| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York
ABSTRACT I. INTRODUCTION A. PKC Isoform Structure B. PKC Activation and Localization Mechanisms in Cells C. PKC Interactions With RACK Proteins II. THE C1 DOMAIN A. C1 Domain Structure B. C1 Domain Lipid Binding Affinities C. C1 Domain-Mediated Subcellular Targeting D. C1A-C1B Interdomain Regions and PKC Targeting E. PKCdelta-C1 Domain Tyrosine Phosphorylation III. THE C2 DOMAIN A. C2 Domain Structure and Lipid Binding B. PKC-C2 Domains as Protein-Protein Interaction Motifs IV. THE KINASE DOMAIN A. cPKC Priming Phosphorylations B. nPKC Serine/Threonine Phosphorylations 1. The molecular determinants of PKCdelta activity: activation loop phosphorylation versus other mechanisms 2. The controls of nPKC activation loop phosphorylation 3. The controls and consequences of nPKC COOH-terminal phosphorylations C. Kinase Domain Tyrosine Residues D. Kinase Domain Features That Distinguish aPKCs From cPKC/nPKC Isoforms V. THE HINGE REGION A. Caspase Cleavage at the Hinge Region B. PKCalpha-D294G Mutation C. PKCdelta-Tyr311 and -Tyr332 Phosphorylation VI. THE V5 DOMAIN A. PKCβ V5 Domain Splice Variants With Distinct Subcellular Targeting and Signaling Functions B. The V5 Domain and PKC Catalytic Function C. The V5 Domain and PLD Activation D. V5 Domain and Nuclear Localization Signals E. V5 Domain Tyr Phosphorylation VII. NONTRADITIONAL PKC ACTIVATION MECHANISMS A. Cellular Actions of Freed Kinase Domains B. Kinase-Independent Actions of Freed Regulatory Domains C. PKC Regulation by Reactive Oxygen Species D. PKC Regulation by Reactive Nitrogen Species VIII. OBSTACLES THAT STYMIE EFFORTS TO RESOLVE PKC ISOFORM-SPECIFIC FUNCTIONS A. PKC Isoform Cross-Talk in Cells 1. PKC activity controls the spatiotemporal dynamics of PKC signaling in cells 2. PKC activity regulates lipid metabolic enzymes that control DAG accumulation in cells 3. PKCvarepsilon-PKCdelta cross-talk in cell culture models and genetically engineered mice B. Some PKC-Directed Antibodies Are State Specific C. Results of PKC Activity Assays Can Vary, Depending on Assay Conditions IX. CHALLENGES AND OPPORTUNITIES FOR FUTURE RESEARCH: IDENTIFICATION OF CELLULAR TARGETS FOR INDIVIDUAL PKC ISOFORMS A. Genetically Engineered Kinases B. FRET-Based Reporters That Track Intracellular PKC Activity X. CONCLUSIONS GRANTS ACKNOWLEDGMENTS REFERENCES
 | ABSTRACT |
|---|
 Top NextReferences |
|---|
| I. INTRODUCTION |
|---|
|
TopPreviousNextReferences |
|---|
PKC isoforms are members of the AGC (PKA, PKG, PKC) family of protein kinases that share certain basic structural features (Fig. 1). These kinases contain a highly conserved catalytic domain (consisting of motifs required for ATP/substrate-binding and catalysis) and a regulatory domain that maintains the enzyme in an inactive conformation. PKC regulatory domains reside in the NH2 terminus of the protein and contain an autoinhibitory pseudosubstrate domain (a sequence that contains an alanine in place of the serine/threonine phosphoacceptor site, but otherwise resembles a PKC substrate) and two discrete membrane targeting modules, termed C1 and C2. PKC isoforms are broadly subdivided into three subfamilies based on differences in their NH2-terminal regulatory domain structure. The regulatory domains of conventional PKC isoforms (cPKCs; 
, βI, and the alternatively spliced βII which contains an additional 43 residues at the NH2 terminus, and 
) contain a C1 domain (consisting of tandem 
50 residue long sequences, termed C1A and C1B, each with 6 cysteines and 2 histidines that coordinate two Zn2+) that functions as a DAG-/PMA-binding motif. cPKC regulatory domains also contain a C2 domain that binds anionic phospholipids in a calcium-dependent manner (Figs. 1–3). Novel PKCs (nPKCs, which can be further subdivided based on structural features into the related 
/
and 
/
isoforms) also have twin C1 domains and a C2 domain (although the ordering of nPKC isoform C1 and C2 domains, along the linear sequence of the protein, is switched relative to the order in cPKCs; Fig. 1). Importantly, nPKC C2 domains lack the critical calcium-coordinating acidic residues (i.e., the determinants for calcium binding). This difference in C2 domain structure in large part underlies the distinct pharmacology of cPKC and nPKC isoforms. nPKCs are maximally activated by agonists that promote DAG accumulation or by PMA, without a calcium requirement. Atypical PKCs (aPKCs; 
and 
/
) lack a calcium-sensitive C2 domain; they contain an atypical C1 domain (with only one cysteine-rich membrane-targeting structure) that binds PIP3 or ceramide (not DAG or PMA) and a protein-protein interaction PB1 (Phox and Bem 1) domain that mediates interactions with other PB1-containing scaffolding proteins [including p62, partitioning defective-6 (PAR-6), and MEK5; Refs. 138, 139]. aPKC activity is regulated primarily by protein-protein interactions and phosphorylation by phosphoinositide-dependent kinase-1 (PDK-1, another AGC kinase family member that contains a PH domain that localizes the enzyme to PIP3-enriched membranes). While some PKC isoforms are expressed in a tissue-specific manner (i.e., PKC is expressed primarily by skeletal muscle, lymphoid organs, and hematopoietic cell lines and PKC is detected largely in neuronal tissues), most PKC isoforms are ubiquitous and many cells coexpress multiple PKC family members.
|
|
The traditional model of PKC activation derives from early studies of PKC which localizes to the cytosol of resting cells; PKC interacts only weakly/transiently with membranes in the absence of calcium or DAG. Agonists that promote phosphoinositide hydrolysis and IP3 generation lead to the mobilization of intracellular calcium, a soluble ligand that binds to the C2 domain and increases its affinity for membranes. This initial electrostatic interaction of the PKC-C2 domain with membranes is relatively low affinity. However, once anchored to membranes, PKC diffuses within the plane of the lipid bilayer and participates in a secondary C1A domain interaction with DAG (the membrane-restricted product of phosphoinositide hydrolysis). Membrane phosphatidylserine (PS) plays a critical role in this secondary membrane interaction, since PS disrupts a electrostatic C1A/C2 interdomain interaction, freeing the C1A domain so that it can penetrate the lipid bilayer and bind DAG (198). C1A binding to membranes also is relatively low affinity. However, the combined energy from the coordinate C1/C2 domain engagement with membranes leads to high-affinity cPKC binding to membranes and a conformational change that expels the autoinhibitory pseudosubstrate domain from the substrate-binding pocket and facilitates PKC activation.
PKC translocation to the plasma membrane generally has been considered the hallmark of activation (and frequently has been used as a surrogate measure of PKC isoform activation in cells). However, this simple model of PKC activation is not sufficient to explain the complex spatiotemporal controls of PKC localization in cells. For example, cPKCs (PKC, PKCβI, and PKCβII) rapidly/transiently translocate to the plasma membrane via a mechanism that involves PLC-derived DAG accumulation. However, in cells that display a biphasic DAG response, PKC and PKCβII (but not PKCβI) are released from the plasma membrane via a regulated process that requires PKC catalytic activity (and variably has been attributed to PKC autophosphorylation; Refs. 55, 56). PKC/PKCβII then accumulate at a perinuclear site dubbed the "pericentron" (a subset of recycling endosomes containing the small GTPase Rab11; Refs. 10, 80) as a result of sustained DAG formation through a PLC-independent mechanism involving phospholipase D (PLD); PLD is a membrane-bound enzyme that generates phosphatidic acid (PA; through the hydrolysis of phosphatidylcholine), which is subsequently converted to DAG by PA phosphohydrolase (77). A different lipid, namely ceramide, acts as an inhibitory regulator of PKC/PKCβII signaling at perinuclear membranes by inhibiting pericentron formation and stimulating a ceramide-activated protein phosphatase (tentatively identified as PP1) that reverses PKC/PKCβII activation loop phosphorylation (a modification described in greater detail in sect. IVA; Refs. 11, 97). PKC/PKCβII localized to the "pericentron" play an important role to "set" hormone responses by controlling the trafficking of continuously recycling membrane signaling proteins such as caveolin-1 and certain cell surface receptors. This chronic PKC signaling response has been implicated in the pathogenesis of clinical disorders such as oncogenic transformation by Ras, hyperglycemia, and Gq-triggered cardiac hypertrophy (220, 223).
PKC isoforms also translocate to specialized membrane compartments such as lipid rafts or caveolae (154). Lipid rafts are sphingolipid-/cholesterol-enriched plasma membrane microdomains that contribute to signal transduction by coalescing into large platforms that concentrate signaling complexes. Caveolae are the sphingolipid-/cholesterol-enriched detergent-resistant membranes that form flasklike invaginations of the plasma membrane in cells expressing caveolin. While the precise relationship between lipid rafts and caveolae remains the focus of considerable controversy (and is beyond the scope of this review), ceramide has recently emerged as an important PKC-regulated lipid in raft/caveolae. Ceramide (formed in lipid rafts) provides the driving force for raft fusion into platforms. PKC regulates ceramide formation. Acid sphingomyelinase (ASM), an enzyme that catalyzes the hydrolysis of sphingomyelin to form ceramide at the plasma membrane, is a PKC-activated enzyme (235). PKC binds ASM and promotes ASM-S508 phosphorylation, leading to ASM recruitment to the plasma membrane and ASM activation. This effect of PKC to promote local ceramide accumulation at the plasma membrane drives raft fusion (providing a nonspecific mechanism to localize signaling proteins such as PKCs to membrane rafts). Local ceramide formation also leads to the recruitment and activation (i.e., activation loop phosphorylation) of PKC in this compartment (140). 14-3-3 proteins are a family of scaffolding proteins that control cell growth/apoptosis pathways and are general inhibitors of PKCs that have been implicated in ceramide-dependent PKC activation; ceramide activates PKC at least in part by dissociating PKC-14-3-3 complexes. The 14-3-3 proteins interact with their binding partners through specific RSXpSXP or RXXXpSXP recognition domains (where pS represents phosphorylated Ser and X represents any amino acid; Ref. 143). While the molecular determinants for PKC-14-3-3 interactions have not been identified, two putative 14-3-3-binding motifs have been mapped to the NH2- and COOH-terminal sequences (101HKFRLHSYSSPT112 and 141RCVRSVPSLCG151, Fig. 2) that form the base of the PKC C1B domain, opposite from the lipid-binding surface. However, a serine phosphorylation that would control this 14-3-3 protein interaction has never been identified. Peptides based on these sequences compete with PKC for 14-3-3 binding in vitro and promote PKC translocation to membranes in vivo (presumably by releasing PKC from the inhibitory constraints imposed by 14-3-3 binding). These peptides can be used to activate PKC in lens epithelial cells, leading to increased PKC-dependent phosphorylation of the gap junction protein connexin 43 (Cx43 at S368) and disassembly of gap junction, suggesting that 14-3-3 proteins that control PKC isoform activation might be targeted for therapeutic advantage.
|
, PKC, and PKC, but not PKC; Refs. 116, 148). Caveolin-1 binding serves to decrease PKC and PKC catalytic activity. While some have speculated that this is attributable to a direct interaction between the caveolin scaffolding domain (a short membrane proximal region of the caveolin NH2 terminus that serves as a protein docking motif) and a caveolin interacting motif (
XXXXX or XXXXXX, where is a hydrophobic residue) found at similar locations in the kinase domains of PKC and PKC, and that caveolin-bound PKC represents a pool of membrane-associated enzyme poised for activation, this model has never been directly verified (148) (and other mechanisms also are likely to anchor/regulate PKCs at this destination). We previously demonstrated that caveolae isolated from resting neonatal rat cardiomyocytes contain little to no phorbol ester-sensitive PKC isoforms and that PKC, PKC, and PKC accumulate in the caveolae fraction in cardiomyocytes treated with PMA (175). Our recent studies provide surprising evidence that 1-adrenergic receptor (1-AR) activation does not lead to PKC/PKC translocation to the caveolae fraction [(171) although 1-ARs induce a robust increase in PLC activity leading to DAG accumulation and PKC/PKC translocation to a light sarcolemmal membrane fraction in this preparation; unpublished data]. These results suggest that 1) 1-ARs do not promote DAG accumulation in caveolae membranes, either because the density of 1-ARs or their downstream signaling partners is limiting in cardiomyocytes caveolae; or 2) 1-ARs increase DAG, but a locally active diacyglycerol kinase (DGK) converts DAG to PA, locally depleting DAG. In fact, norepinephrine has recently been reported to activate DGK- in the caveolae/raft fraction of rat mesenteric small arteries (32), although the relevance of this finding to PKC regulation in cardiomyocytes, where a different DGK isoform, namely, DGK-, negatively regulates hypertrophic signaling responses, remains uncertain (5, 210). Irrespective of mechanism, these results emphasize that phorbol esters may be imperfect reagents to explore PKC localization to lipid raft membranes or the physiological controls of PKCs by lipid cofactors that are generated endogenously in growth factor-stimulated cells. Certain PKCs also accumulate in the Golgi or in the nucleus. These other PKC localization mechanisms are discussed in greater detail in the sections that follow.
C. PKC Interactions With RACK Proteins
Models of PKC activation have generally focused on the intramolecular interaction between the pseudosubstrate domain and the catalytic pocket; PKC mutations that disrupt this intramolecular interaction (such as a pseudosubstrate domain deletion or an alanine
glutamate phosphomimetic substitution in the pseudosubstrate domain sequence) generate constitutively active forms of PKC that partition to membranes. However, research from the Mochly-Rosen laboratory has focused on a second intramolecular interaction that is based upon PKC interactions with receptors for activated C kinase (RACKs), a family of membrane-associated PKC anchoring proteins that act as molecular scaffolds to localize individual PKCs to distinct membrane microdomains in close proximity with their allosteric activators and unique intracellular substrates. These investigators have proposed that cells express a unique RACK (with a distinct subcellular localization) for each PKC isoform and that PKC-RACK interactions are essential for isoform-specific cellular responses. To date, proteins with characteristics of RACKs (i.e., proteins that selectively/saturably bind only the active conformation of the cognate PKC isoform and recruit the enzyme in an active conformation to a specific membrane compartment) have been identified for PKCβ (RACK1) and PKC (RACK2 or β-COP; Table 1; Refs. 37, 128, 181). These RACK proteins share a seven-WD40-motif repeat structure, similar to the protein-protein binding motifs found in heterotrimeric G protein β-subunits. In the case of RACK1, the PKCβ binding site (SIKIWD) maps to the end of the sixth WD40 motif and is homologous to sequences in three other WD40 repeats in this protein (and distinct from the sequences found at similar regions of heterotrimeric G protein β-subunit structures; Ref. 168). The identity of the PKC RACK protein is less straightforward. Robles-Flores et al. (166) have identified p32/gC1qBP as a PKC binding partner that resides in the Triton-insoluble cell fraction and exhibits properties of a RACK. p32/gC1qBP associates only with allosterically activated PKC (and colocalizes with PKC to the nucleus) in PMA-treated cells (166). However, p32/gC1qBP constitutively interacts with PKC (i.e., it is a PKC binding partner, not a PKC-RACK). p32/gC1qBP and PKC translocate as a complex from the cytosol to the perinucelar region and the cell nucleus in response to PMA. Kheifets et al. (96) have recently identified an additional PKC localization mechanism involving annexin V, a cytoskeletal protein with a short stretch of sequence homology to PKC. These investigators used FRET technology to show that PMA promotes an interaction between PKC and annexin V in the cytosol and that this interaction precedes (and is required for) subsequent PKC translocation to membranes (96). These results have been taken as tentative evidence that annexin V serves as a shuttle protein on microtubules to transport PKC to its site of action (and its bone fide RACK) in the particulate fraction.
|
RACK sequence, Table 1) and that these sequences participate in an intramolecular interaction that maintains the enzyme in an inactive conformation at rest; this interaction must be disrupted for PKC activation. RACK sequences with close (albeit imperfect) homology to actual PKC binding sites on the respective RACK protein have been identified in PKCβ, PKC, and PKC. In each case, a single charge change lowers the affinity of the intramolecular interaction, presumably allowing displacement of the RACK sequence and favor PKC binding to its bona fide membrane-anchored RACK protein upon PKC activation. Mutagenesis studies support this model, showing that a single 85H(DN)APIGYD92 mutation in the PKC RACK sequence (which generates a RACK sequence more closely mimicking the bona fide PKC binding sequence in β'COP) renders PKC resistant to proteolysis and agonist-dependent translocation to membranes (i.e., it increases the intramolecular interaction that maintains PKC in a closed, inactive conformation), whereas a PKC-85H(DA)APIGYD92 mutation generates an enzyme that translocates to membrane more rapidly than WT-PKC, suggesting that the D86A mutation weakens the intramolecular contact (180).
Peptides based on RACK binding sites have been developed as PKC isoform-selective translocation inhibitors that competitively inhibit PKC docking to its specific membrane anchoring RACK protein. Similarly, peptides based on RACK sequences have been used as allosteric PKC agonists; the notion being that the RACK sequence binds to the RACK-binding sites, interferes with the autoinhibitory intramolecular interaction between the RACK-binding site and the RACK sequence, and destabilizes the inactive "closed" conformation of the enzyme. The use of peptide modulators of PKC translocation offers an advantage over traditional overexpression strategies in that it alters PKC signaling without disturbing the natural stoichiometry of any given PKC isoform to its upstream activators or downstream substrates. However, it is important to note that RACK proteins may be key for some aspects of PKC localization and activation in cells, but there is ample evidence that PKCs localize in cells via RACK-independent interactions with cytoskeletal proteins (such as actin and tubulin) and true scaffolding proteins (such as caveolin and A-kinase anchoring proteins). Moreover, RACK proteins fulfill many cellular functions that are completely unrelated to PKC (i.e., as scaffolds that organize signaling complexes involving Src family kinases, G protein β subunits, dynamin, integrins, STAT1, the receptor protein tyrosine phosphatase PTPµ, and phosphodiesterase 4D5; Ref. 130). A complete understanding of the full biological consequences of treatments with peptides designed to modulate PKC translocation will require further studies.
Attempts to generate crystals of full-length PKC suitable for high-resolution three-dimensional structural analyses have not been successful. Nevertheless, high-resolution crystal structures of individual PKC regulatory motifs (including the C1 domain of PKC, PKC, and PKC and the C2 domains of PKC, PKCβ, PKC, and PKC) as well as the catalytic domains of PKCβII, PKC, PKC, and related AGC kinases (notably PKA and AKT) have been published (75, 100, 101, 133, 145, 151, 208, 215, 225, 226, 231, 237). Newer concepts regarding the molecular determinants of PKC isoform-specific functions based on these X-ray crystal structures as well as more traditional biochemical and mutagenesis approaches are reviewed in the sections that follow.
| II. THE C1 DOMAIN |
|---|
|
TopPreviousNextReferences |
|---|
C1 domains were first identified as highly conserved DAG/PMA binding sites in PKCs with a characteristic HX12CX2CXnCX2CX4HX2CX7C motif, where H is histidine, C is cysteine, X is any other amino acid, and n is 13 or 14 (Fig. 2). While this motif duplicated in tandem is a characteristic feature of cPKCs and nPKCs, high-affinity PMA-binding C1 domains also are found in proteins that lack kinase domains such as the chimaerins (a family of Rac GTPase activating proteins), RasGRPs (Ras/Rap1 exchange factors), and Munc13 isoforms (scaffolding proteins involved in exocytosis). C1 domains that lack structural determinants for PMA binding also are found in aPKCs, Raf-1, DAG kinases, and Vav (93).
High-resolution crystal structures of PKC, PKC, and PKC C1B domains (complexed with phorbol esters) have been published; these C1 domains adopt similar tertiary structures and function as hydrophobic switches to anchor PKCs to membranes (75, 225, 237). The upper third of the C1 domain forms a largely hydrophobic surface. Positively charged residues that interact with anionic phospholipids are exposed on the middle third of the C1 domain structure. The bottom third of the C1 domain contains the two Zn2+-coordinating sites (each formed by three cysteines and one histidine) that are required for proper C1 domain folding. C1 domain positively charged residues initially interact with electrostatically anionic membrane phospholipids. This initial interaction positions the C1 domain to penetrate the membrane bilayer and bind DAG, which is located more deeply within the membrane structure. Lipid cofactors such as DAG or PMA then bind to a narrow polar groove in the otherwise highly conserved hydrophobic surface at the top of the C1 domain (formed by the C1A-Trp58/Phe60 pair and the C1B-Tyr123/Leu125 pairs in PKC-C1a and C1b domains, and cognate residues in other PKC isoforms, Fig. 2). By capping this hydrophilic ligand-binding pocket (i.e., generating a continuous hydrophobic surface), lipid cofactors act as "molecular glue" to increase C1 domain affinity for membranes (31, 78). Some C1 domains (such as the C1 domain of PKC) appear to be buried in the resting state and exposed (becoming accessible to DAG/PMA) only following the conformational change that accompanies calcium-dependent membrane binding.
Early studies provided unambiguous evidence that a single C1 domain contains the structural determinants to support full-length PKC binding to DAG-/PMA-containing membranes (i.e., aPKCs are DAG/PMA-unresponsive due to an intrinsic difference in the properties of their C1 domains, and not because they have only one C1 domain). The structural features that distinguish DAG-/PMA-sensitive C1 domains in cPKCs and nPKCs from PMA-insensitive aPKC C1 domains have recently been identified. The NH2-terminal half of aPKC C1 domains contain a cluster of basic residues (HLFQAKRFNRRAYCGQCSERI) that are not found in PMA-sensitive C1 domains (Fig. 2). Modeling studies (based on the PKC-C1 domain structure) suggest that the adjacent Arg-Arg residues in the middle of this sequence are exposed on the protein surface. This portion of the PKC C1 domain sequence functions as a nuclear localization sequence (NLS) when fused to GFP (155). Recent studies also indicate that this portion of the C1 domain also influences lipid responsiveness, since PKC can be converted to a PMA-sensitive enzyme simply by substituting the four arginine residues in this sequence to the corresponding (uncharged) residues from the PKC-C1b domain (160). Conversely, the PKC-C1b domain is rendered PMA-insensitive by arginine substitutions at these positions. The relative importance of the C1 domain basic cluster as a NLS (that drives full-length PKC to the nucleus) versus as a regulator of aPKC-lipid (both DAG and PIP3) interactions requires further study.
B. C1 Domain Lipid Binding Affinities
C1A and C1B domains of PKC and PKC bind both DAG and phorbol esters with high affinity; both domains contribute to full-length PKC and PKC binding to membranes (195). In contrast, other PKC-C1 domains display a wide range of affinities for lipid cofactors (ranging from 1 nM to >3 µM). In fact, the C1A and C1B domains of certain PKC isoforms have opposite intrinsic affinities for DAG and phorbol esters. For example, the C1A domains of PKC and PKC have high affinity for DAG; mutagenesis studies implicate the C1A domain in DAG-dependent activation of full-length PKC or PKC. In contrast, phorbol esters activate PKC and PKC through a high-affinity interaction at C1B. While PKC and PKC C1B domains are DAG-responsive, DAG binds with higher affinity to the PKC C1A domain than to the PKC C1B domain. PKC and PKCβII C1B domain interactions with DAG are too weak to contribute to membrane binding under physiological conditions (47, 195, 196). However, while DAG activates full-length PKC, PKCβII, PKC, and PKC through a C1A domain-dependent mechanism, DAG interacts with high affinity to the PKC C1B (not C1A) domain (132). The structural basis for isoform-specific differences in C1B domain affinity for DAG was recently mapped to an invariant tryptophan residue that is conserved in the lipid-binding surface of nPKCs (that bind DAG-containing membranes with high affinity) and is replaced by a tyrosine in cPKC C1B domains (Y123 in PKC). Dries et al. (47) recently used a cell imaging approach with YFP-tagged C1B constructs to show that a single Tyr-Trp substitution at this site converts the PKCβ-C1B domain into a DAG binding module. However, other studies identify mechanisms outside the C1 domain that regulate DAG binding. An intramolecular interaction between acidic V5 domain residues (D649, D652, and E654; Fig. 6) and C2 domain lysine-rich cluster stabilizes the closed DAG-insensitive conformation of PKC. The DAG sensitivity of PKC is enhanced by V5 domain truncation, overexpression of a V5 domain peptide (which is presumed to disrupt V5-dependent intramolecular interactions), V5 domain autophosphorylation site alanine substitutions, or mutations that reverse charge at the V5 domain acidic residue cluster (a maneuver that would disrupt this intramolecular interaction; Ref. 205).
|
from the cytoplasm to the membrane (79) and PKC/PKC from the cytosol to the Golgi (91; although an effect of ceramide to release PKC and PKC from membranes also has been reported, Ref. 178). Arachidonic acid mimics the effect of ceramide to translocate PKC from the cytosol to the Golgi, whereas arachidonic acid does not alter the subcellular localization of PKC (and it inhibits PKC translocation to surface membranes, Ref. 144). Mutagenesis and domain swapping experiments indicate that ceramide activates PKC and PKC via an interaction with the C1B domain, arachidonic acid activates PKC via an interaction with the C1B domain (91), whereas arachidonic acid inhibits PKC via an interaction with the C1A domain (145).
Electrostatic interactions of individual PKC C1 domains with anionic phospholipids (i.e., the PS requirement for membrane binding and enzyme activity) also differ. The C1 domains of PKC, PKCβ, and PKC show strong preference for PS over other lipid species, whereas the C1 domains of PKC and PKC do not (64, 187, 195, 196, 198). Studies of PKC indicate that PS plays an important role to disrupt intramolecular tethers (involving electrostatic Asp55-Arg252 and Arg42-Glu282 interactions) that maintain PKC in a closed conformation in the resting state (Figs. 2 and 3). Conventional wisdom holds that PS releases these intramolecular tethers, allowing the C1A domain to partially penetrate the membrane, bind DAG, and trigger the conformational changes that lead to enzyme activation. In support of this model, single residue substitutions at any one of the four residues that form C1A-C2 tethering ion pairs (i.e., at Asp-55, Arg-252, Arg-42, or Glu-282) increase PKC's membrane affinity, increase its basal activity, and abrogate its PS requirement. Moreover, double charge reversals (Asp55Lys/Arg252Glu or Arg42Glu/Glu282Arg substitutions) largely restore WT membrane binding affinity (198). However, an inaccessible C1A domain is not a defining feature of all cPKC, since PKC C1A and C1B domains are reported to be conformationally flexible; they penetrate the membrane and bind DAG, without a PS requirement (3).
C. C1 Domain-Mediated Subcellular Targeting
The conventional model of PKC activation focuses on effects of DAG or PMA to anchor PKCs to the plasma membrane. However, it has become increasingly evident that PKCs have many destinations in cells. As noted in the previous section, the NH2-terminal half of aPKC C1 domains contain a basic cluster that acts as a NLS when fused to GFP (independent of any zinc finger structure). For PKCs that lack a C1 domain NLS, translocation patterns (to the plasma membrane, lipid rafts, nuclear membranes, Golgi, endoplasmic reticulum, and mitochondria) can vary substantially depending on the cell type and particular stimulus. Several laboratories have examined whether C1 domains (that inherently differ in their affinities for various lipid cofactors) play a specific role to drive full-length PKC to specific intracellular membranes with distinct lipid compositions. These studies implicate the tandem C1 domains in cPKC/nPKC isoforms in mechanisms that provide for a high level of spatiotemporal control of PKC localization. In general, the tandom C1 domains are not functionally redundant.
The Blumberg laboratory has demonstrated that PKC localizes to distinct subcellular compartments through C1 domain-mediated interactions that are influenced by the hydrophobicity (i.e., fatty acid side chain length) of the phorbol ester used in the experiment. They used phorbol ester derivatives with different fatty acid side chain lengths (that bind C1 domains with comparable affinities) to show that very hydrophobic phorbol ester derivatives drive PKC to the plasma membrane, derivatives with intermediate hydrophobicity drive PKC to the plasma membrane followed by redistribution of PKC to the nucleus, and more hydrophilic phorbol esters translocate PKC primarily to the nuclear membrane (hydrophilic phorbol esters do not drive PKC to the plasma membrane; Ref. 218). However, Cho and colleagues (196) performed similar studies and obtained a somewhat different result, showing that relatively hydrophilic short-chain DAGs (that distribute to both surface and internal cell membranes) selectively drive PKC to the PS-enriched plasma membrane (i.e., PS cooperates with DAG to localize PKC to surface membranes). The discrepant findings between these two laboratories are not readily reconciled and will require additional studies, including with newer technologies.
PKC targeting as a result of C1 domain interactions with proteins also has been reported. As noted in section IB, PKC localization to membranes is inhibited as a result of a C1B domain interaction with 14-3-3 (143). Other studies show that the PKC C1B domain interacts with fascin, an actin-bundling protein that plays a role in cell adhesion and spreading on fibronectin (4) and that the PKCβII C1A domain binds the centrosomal protein pericentrin (to control microtubule organization, spindle assembly, and chromosome segregation during cell division) (28). nPKCs (including in PKC, PKC, PKC, and PKC) also localize through their C1B domain to the Golgi complex where they play a role in specific cellular functions (i.e., PKC and the related PKC induce apoptosis, whereas PKC modulates secretion from the Golgi complex; Refs. 37, 90, 183). nPKC C1A domains lack a Golgi localization signal and do not drive full-length PKC, PKC, PKC, or PKC to the Golgi complex (129, 182). While some studies have focused on ceramide as a lipid cofactor that localizes PKC and PKC (through their C1B domains) to the Golgi (91; see sect. IB), Larsson and colleagues (183) have used sequence alignment, structural modeling, and mutagenesis studies to implicate a conserved C1B domain methionine (Met267 in the C1B domain of PKC) as a Golgi localization signal, showing that 1) this residue lies outside the C1 domain lipid binding surface; 2) a methionine or similar residue at this position is a highly conserved feature of C1 domains that localize to Golgi (including the C1B domains of PKCs, the C1A domain of PKD, and the C1 domain of β-chimaerin), but not C1 domains that accumulate at other cellular membranes; and 3) a single M267G substitution is sufficient to fully abrogate PKC localization to Golgi (and the resultant apoptosis) without interfering with PMA-dependent PKC translocation to the nucleus.
The C1B domain also has been implicated as a structural determinant of PKC trafficking and activity during oxidative stress in lens epithelial cells. Here, low H2O2 concentrations (100 µM) lead to oxidative modification of PKC, increased PKC activity, and PKC translocation to caveolae membranes, where PKC interacts with caveolin-1 and the junctional gap protein Cx43, increases Cx43-S368 phosphorylation, and inhibits gap junction activity (115). This mechanism results in decreased transcellular transmission of proapoptotic signals and is cytoprotective in lens epithelia. The importance of this PKC-dependent mechanism has been established in PKC knockout mice where oxidative stress leads to exaggerated lens opacification (113). Of note, missense mutations localized to key regions of the PKC C1B domain (H101Y, G118D, S119P, and G128D) disrupt C1B domain structure and are implicated in the neurological disorder autosomal dominant nonepisodic cerebellar ataxia (Fig. 2; Refs. 29, 214). Studies in a more reductionist cell culture model indicate that PKC harboring C1B domain mutations displays low basal activity and is not activated by H2O2; in fact, these mutant forms of PKC act in a dominant inhibitory manner to prevent WT-PKC activation by H2O2, leading to a loss of PKC-dependent gap junction inhibition and increased apoptosis in lens epithelial cells (114). Cx43 also has been implicated as a target (and binding partner) for PKC in cardiomyocytes (46). Here, Cx43 phosphorylation has been attributed to PKC mapped to Cx43-S262. Cx43-S262 phosphorylation is implicated as a mechanisms that decreases gap junction permeability and intercellular communication (45).
D. C1A-C1B Interdomain Regions and PKC Targeting
Thuille et al. (212) recently identified NSRET219MF (which lies between the twin C1 domains) as a major autophosphorylation site in PKC. In contrast to the constitutive priming phosphorylations at the activation loop and hydrophobic motif that are retained in resting Jurkat and T cells (see sect. IVA), PKC is not phosphorylated at T219 in resting T cells. PKC-T219 phosphorylation is induced by phorbol 12,13-dibutyrate (PDBu), vanadate, and antigen receptor cross-linking. T219 phosphorylation is essential for PKC-dependent antigen receptor signaling responses; a PKC-T219A mutant exhibits WT in vitro catalytic activity and lipid binding activity, but PKC-T219A localizes aberrantly to the detergent-insoluble fraction of resting T cells, is not recruited to the T cell receptor (TCR) in lipid rafts, and fails to support NF
B activation. These results suggest that T219 phosphorylation is critical for proper PKC targeting to the TCR in lipid raft membranes. Of note, the T219 phosphorylation motif (NSRET219MF) in the C1A-C1B interdomain region of PKC is conserved in PKC (NSRDT218IF), but not in any other PKC isoform (although a potential regulatory role for PKC-T218 phosphorylation has never been considered).
PKC does not share sequence homology with PKC/PKC at this interdomain position. Nevertheless, residues within the PKC C1 interdomain region (LKKQET) bind F-actin and localize PKC in an activated form to the cytoskeletal fraction (157, 158). Other studies have focused on a different RFX(V/I)XMP sequence that is immediately NH2-terminal to the C1B domain and is highly conserved in PKC, PKC, and PKC (PKC isoforms that have the capacity to induce neurite outgrowth in neuroblastoma cells). This sequence is not conserved in cPKCs that do not induce neurite outgrowth (118, 158). Mutagenesis studies identify a critical role for the F237, V239, and M241 (numbering based upon PKC); PKC mutants harboring substitutions at these hydrophobic sites localize to the plasma membrane, but they do not induce neurite outgrowth. These results have fueled speculation that the region between the C1A and C1B domains represents an exposed surface on the active enzyme and functions as a protein-protein interaction "hot spot" that is critical for proper PKC targeting in cells. Indeed, recent studies also identify an Asn residue at the COOH terminus of the C1B domain that is unique to the PKC and PKC (i.e., is not found in other PKC isoforms) that is critical for neurite-inducing capacity; this Asn residue models to a position at the base of the C1 domain opposite from the lipid binding surface (117).
E. PKC-C1 Domain Tyrosine Phosphorylation
Two tyrosine residues in the PKC C1A domain have been identified as sites for functionally important phosphorylations. PKC-Y155 (which is flanked by the pseudosubstrate motif and the C1A domain and is unique to PKC) has been implicated in PKC-dependent growth responses. In certain heterologous overexpression systems, WT-PKC overexpression slows proliferation, whereas a single Y155F-substitution is sufficient to link PKC to an enhanced growth response (1, 104, 219). The mechanism(s) that control PKC-Y155 phosphorylation or the downstream signals linking the PKC-Y155F mutant to altered growth regulation have not been examined. PKC phosphorylation at Y187 (a site conserved in other nPKC isoforms) has been reported in some cells treated with PMA and platelet-derived growth factor (PDGF) (104, 111). PKC-Y187 phosphorylation does not influence PKC kinase activity (in vitro, using a pseudosubtrate domain peptide), and heterologously overexpressed PKC-Y187F mimics the effect of WT-PKC to inhibit growth in NIH3T3 and C6 glial cells and to induce the monocyte differentiation program in 32D myeloid progenitor cells (111, 219). However, PKC-Y187F does not mimic the effect of WT-PKC to promote differentiation in C6 glial cells (104). Again, the molecular mechanisms that account for altered signaling by the PKC-Y187F mutant have not been identified.
| III. THE C2 DOMAIN |
|---|
|
TopPreviousNextReferences |
|---|
C2 domains were first described as 130 residue sequences that function as calcium-dependent membrane-binding modules in the regulatory domain of cPKCs. C2 domains were subsequently identified in many proteins that participate in membrane trafficking and signal transduction. C2 domains share a common tertiary structure comprised of eight anti-parallel β-strands connected by variable loops. In general, C2 domains share more structural homology in the core β-sandwich portion of the domain (which play a more structural scaffolding role) than in the loop sequences, which are more divergent and dictate functional specificity. Detailed structural studies of PKC suggest that two or three calcium ions bind in a highly cooperative manner to several highly conserved Asp residues in the calcium-binding loops (D187, D193, D246, D248, and D254 in PKC) that connect the β-stands at the top of the domain structure (131). nPKC C2 domains lack these calcium-coordinating residues in their loop sequences and therefore bind membranes in a calcium-independent manner. Further structural studies of PKC show that Asn189 plays an important role in the mechanisms that render PKC selective for PS (over other anionic phospholipids), Arg249/Arg252 contribute to PKC's electrostatic interactions with the anionic membrane surface, Trp245/Trp247 are involved in hydrophobic interactions with membrane, and the highly basic lysine-rich β3- and β4-sheets localize active PKC to PIP2-enriched membranes (34, 51, 54, 131, 197). While early studies from the Parker laboratory identified a Thr250 (a threonine residue that is strategically located in the calcium binding loop of PKC and is highly conserved in other cPKCs) as an autophosphorylation site (142, 159), the importance of C2 domain threonine autophosphorylation as a mechanism to regulate PKC interaction with membranes has not been revisited.
cPKC C2 domains play important roles as calcium-dependent membrane-targeting modules. However, the isolated PKC-C2 domain does not bind lipid (and the C2-domain deleted forms of full-length PKC shows no membrane targeting defect; Refs. 64, 196). Newton et al. (64) have speculated that the very high intrinsic affinity of the PKC-C1 domain for membranes (2 orders of magnitude higher than the C1 domain of cPKCs) may have evolved to compensate for the lipid-binding defect of the PKC C2 domain. Studies of PKC C2 domain function are less consistent. The Corbalan-Garcia laboratory has presented evidence that the PKC C2 domain acts as a lipid-binding domain to anchor PKC to membranes containing DAG and phosphatidic acid (88, 145). In contrast, the Cho laboratory has reported that the PKC C2 domain binds lipids only weakly (with an affinity that is more than 2 orders of magnitude lower than the affinity of the full-length protein) and that the C2 domain deleted forms of full-length PKC show no membrane targeting defect (195).
B. PKC-C2 Domains as Protein-Protein Interaction Motifs
The Mochly-Rosen laboratory has used sequence homology analysis with synaptotagmin (a known RACK1 binding protein) to identify 186MDPNGLSDPYVKL198, 209KQKTKTIK216, and 218SLNPEWNET226 within the PKCβ-C2 domain (along with additional sites in the V5 domain, discussed further in sect. VIA) as RACK1-binding sites (167). These RACK1 binding sites lie on β-strands in the domain, with the 186MDPNGLSDPYVKL198 sequence on strand 3, adjacent and anti-parallel to a RACK1-mimetic sequence (dubbed βRACK, 241SVEIWD246) on strand 6. This spatial orientation would permit an intermolecular strand-strand interaction that stabilizes the β-sandwich structure (8). Peptides based on this PKCβ-C2 domain RACK1 binding sequences inhibit agonist-dependent PKCβII translocation to membranes when introduced into cardiomyocytes or Xenopus oocytes (167).
The C2 domain of PKC (which is not required for membrane translocation) also contains sequence (14EAVSLKPT21) that binds to the RACK β'COP, as well as sequence (85HDAPIGYD92) that is 75% homologous with sequence in β-COP (285NNVALGYD292), the RACK that anchors PKC at its intracellular site of action (19). These sequences are evolutionarily conserved in PKC and are distinct from the cognate sequences in other PKC isoforms; as noted in section IC, these sequences are believed to participate in an intramolecular interaction that stabilizes PKC in an inactive closed conformation that must be interrupted for PKC activation (87, 180).
While the identity of the C2 domain sequence that acts as a RACKs (or RACK binding) site for PKC is less certain, the PKC C2 domain (which adopts a somewhat different conformation relative to other C2 domains) interacts with a number of PKC binding partners, including annexin V, actin, and GAP-43 (a PKC substrate involved in neurite outgrowth) (40, 123, 151). Very recent studies also implicate the PKC C2 domain as a novel phosphotyrosine binding motif that mediates the interaction between PKC and CDCP1 (a transmembrane protein that is tyrosine phosphorylated by Src and overexpressed in colon cancer) (12). Using a degenerated phosphotyrosine peptide library screen, Benes et al. (12) defined an optimal PKC C2 domain consensus binding sequence as (Y/F)-(S/A)-(V/I)-pY-(Q/R)-X-(Y/F) and showed that the PKC C2 domain binds to this sequence with an affinity that compares favorably with the affinities reported for SH2 and PTB domain binding (250–500 nM). However, unlike SH2 and PTB domains (which recognize phosphotyrosine in the context of either COOH- or NH2-terminal sequence), PKC's C2 domain recognizes phosphotyrosines with aromatic residues at both the +3 and –3 positions (i.e., sequence specificity is defined by residues both NH2 and COOH terminal to the phosphotyrosine). These investigators have mapped the phosphopeptide binding sites in the PKC C2 domain to Lys48, His62, and Arg67 (which interact with the phosphate) as well as residues at the COOH and NH2 termini of the C2 domain (that interact with the peptide backbone). It is interesting to note that all of the residues that contribute to phosphopeptide binding are highly conserved in PKC (but not other PKC isoforms); a role for PKC C2 domain as a protein-protein interacting motif is likely, but has not yet been considered. Furthermore, tyrosine residues within or adjacent to the PKC C2 domain phosphopeptide binding surface (namely, Tyr52 and Tyr64) have been identified as targets for functionally important regulatory phosphorylations (89, 151, 191). Tyr52 (which is an in vitro substrate for Lyn, is phosphorylated via a Lyn-dependent mechanism in rat basophilic leukemia cells, and is conserved in PKC; Ref. 209) interacts with the +3 position Tyr in the phosphopeptide binding partner; PKC-Y52 phosphorylation is predicted to influence phosphopeptide binding. Similarly, Tyr64 (which is unique to PKC, and not found in PKC) is optimally positioned to interact with Arg67; a phosphotyrosine at this position in the C2 domain might compete with (and prevent) phosphopeptide binding to the C2 domain. This suggests a mechanism that might underlie previous observations that C2 domain tyrosine phosphorylation plays a critical role to influence PKC's cellular actions and is likely to be a fruitful area for future research.
Finally, there is evidence that the C2 domain of PKC (which is structurally related to PKC) is tyrosine phosphorylated in antigen-stimulated T cells (122). Here, phosphorylation has been mapped to Y90, a tyrosine that is unique to the PKC calcium-insensitive C2 domain (and is not found in the related PKC C2 domain). Other C1 or C2 domain tyrosine residues (such as Y53 and Y188, which correspond to Y52 and Y187 in PKC) are not phosphorylated in antigen-stimulated T cells. PKC-Y90 phosphorylation has been attributed to Lck, which phosphorylates PKC in vitro and constitutively associates with the PKC regulatory domain in vivo; PKC is not tyrosine phosphorylated by other non-receptor tyrosine kinases such as Fyn, Zap-70, or Syk. A functional role for PKC-Y90 phosphorylation has begun to emerge in the literature. While Y90 phosphorylation is not required for PKC-Lck interactions and an initial mutagenesis study failed to link Y90 phosphorylation to changes in PKC targeting to membranes, a recent study implicated Y90 phosphorylation as a mechanism that enhances PKC affinity for lipid membranes (132), and there is evidence that a single Y90F mutation introduced into the constitutively active PKC-A148E mutant is sufficient to fully abrogate PKC biological functions (such as the induction of interleukin-2 promoter NFAT/AP-1 activity and cell proliferation, Ref. 122).
| IV. THE KINASE DOMAIN |
|---|
|
TopPreviousNextReferences |
|---|
bound to staurosporine, and PKC complexed with BIM-1, i.e, a PKC isoform representative of each subfamily; Refs. 72, 133, 226), it has been possible to validate many of the assumptions made in these early studies. PKC catalytic regions share high overall structural alignment with PKA, with most of the residues that are invariant across AGC kinase family members clustering at sites of nucleotide binding or catalysis. Like other AGC kinases, PKC catalytic domains contain a smaller NH2-terminal lobe that is comprised mainly of β-sheets and contains the characteristic glycine-rich ATP-binding loop with the consensus GXGXXG sequence (a structural hallmark of protein kinases and nucleotide binding proteins) and an invariant Lys which structures the enzyme for phosphoryl-transfer (and is generally mutated to generate kinase-inactive mutants, Fig. 4). The COOH-terminal lobe of the kinase domain is predominantly -helical and contains the activation loop segment that positions magnesium and peptide substrates for catalysis followed by the V5 domain at the NH2 terminus (Figs. 5 and 6). A "gatekeeper" residue located in sequence connecting the two lobes of the kinase domain controls access to a preexisting cavity in the ATP binding pocket (Fig. 4). This residue is conserved as a large hydrophobic amino acid in the human kinome; a glycine substitution at this site generates an enzyme that uniquely binds unnatural ATP analogs with bulky substitutions (that do not bind any closely related endogenous enzymes). Gatekeeper residue mutations are the basis of the chemical genetic approaches that have been used to engineer kinases that are uniquely sensitive to certain unnatural inhibitor or activator ATP analogs and provide a powerful and elegant strategy to resolve the physiological substrates of individual kinases in cells (42). Moreover, there is growing evidence that the gatekeeper residue also may play a structural role to constrain the flexibility and autocatalytic activation of certain enzymes (53, 179). Finally, the activation loop and V5 domain contain highly conserved priming/regulatory phosphorylation sites that play a critical role to structure the catalytic pocket; these phosphorylation events are considered in this section, whereas the more structurally divergent V5 domain features (that impart certain aspects of PKC isoform specificity) are considered in greater detail in section VI.
|
|
Traditional models of PKC activation have focused on allosteric activation by calcium and DAG. The "priming" Ser/Thr phosphorylations that lock the enzyme in a closed, stabilized, catalytically-competent, phosphatase/protease-resistant conformation have only recently become the focus of research interest (141, 153). PKCs are first phosphorylated at a threonine residue in the "activation loop," a highly conserved 20–30 residue sequence in the cleft of the kinase domain that is flexible (assumes a different orientation in the active and inactive enzyme) and forms part of the peptide substrate binding surface (Fig. 5). PKC activation loop phosphorylation introduces a negative charge that aligns residues in the catalytic pocket and stabilizes the active conformation of the enzyme. PKC activation loop phosphorylation is generally attributed to PDK-1. However, it is worth noting that the PKA activation loop site can be phosphorylated either by a heterologous kinase with properties resembling PDK-1 or through an autocatalytic mechanism (depending on the in vivo environment). In fact, the observation that PKA activation loop phosphorylation and enzyme activity are similar in PDK1+/+ and PDK1–/– ES cells suggests that PDK1 activity is not necessarily rate limiting for PKA activation loop phosphorylation (23, 136, 222). These results are pertinent to our recent studies of PKC, which undergoes activation loop autophosphorylation under certain circumstances (170; see sect. IVB2, Fig. 5C).
Newly synthesized PKCs are believed to adopt an open conformation that allows PDK-1 access to the exposed unphosphorylated hydrophobic motif sequence in the COOH-terminal V5 domain (48, 62, 192). The prevailing model (based primarily on detailed studies of related AGC kinases) holds that PDK-1 must dock to the hydrophobic motif to be activated and positioned for activation loop phosphorylation. However, it is worth noting that PKC truncation mutants that lack the hydrophobic motif can interact with PDK-1, and they display activation loop phosphorylation (238); these results are surprising and suggest caution when extrapolating conclusions derived from studies of other AGC kinases to PKCs.
Once PDK-1 phosphorylates the activation loop, PDK-1 must be released from the COOH terminus for full maturation of the enzyme (since persistent PDK-1 binding to the COOH terminus would prevent hydrophobic motif autophosphorylation). The cPKCs and nPKCs then undergo two additional phosphorylations at conserved motifs in the COOH-terminal V-5 domain: at a (generally proline-flanked) conserved "turn motif" and at a FXXFS/TF/Y motif (a phosphorylation site bracketed by hydrophobic residues) 19 residues COOH terminal to the "turn motif" (Fig. 6). For cPKCs, these are autophosphorylation reactions that are stable modifications (i.e., completed during the maturation of the enzyme and typically retained during normal culture conditions); the mechanism for nPKCs is less straightforward (and is discussed in sect. IVB3). While hydrophobic motif phosphorylations are a feature of cPKCs and nPKCs, the Ser/Thr phosphorylation site is replaced by a phosphomimetic Glu in aPKCs, and PKA terminates at Phe (the residue immediately preceding the hydrophobic motif S/T phosphorylation site in cPKC/nPKC structures, Fig. 6). X-ray crystal structures of PKA, AKT, and PKC identify an interaction between this phenylalanine (preceding the hydrophobic motif phosphorylation site) and a hydrophobic pocket on the back side of the active site; this interaction stabilizes the catalytic core structure in a position that allows for high-affinity interactions with ATP and substrate (i.e., is favorable for catalysis), suggesting a mechanism whereby COOH-terminal phosphorylations regulate catalytic activity. However, COOH-terminal phosphorylations also appear to control enzyme activity by influencing the thermal stability, detergent solubility, and protease/phosphatase susceptibility of the enzyme. Additional long range effects of the hydrophobic motif to influence regulatory C2 domain interactions with calcium also have been reported (50, 226). Collectively, these three functions for the hydrophobic motif (to dock PDK-1 and thereby support activation loop phosphorylation, to structure the catalytic pocket, and to participate in long-range interactions with the C2 domain) are critical to generate a fully phosphorylated catalytically competent enzyme that is maintained in an autoinhibited conformation in the cytosol, poised to be activated by second messengers. Of note, once fully phosphorylated, cPKCs no longer require a negative charge at the activation loop for catalysis. PKCβII retains catalytic activity when selectively dephosphorylated at the activation loop. However, a turn motif phosphorylation is required for catalytic competence; PKCβII is rendered catalytically inactive when it is expressed as the turn motif, T641A, mutant (or when it is dephosphorylated selectively at the turn motif or generally at all three priming phosphorylation sites; Refs. 16, 49). Isolated reports showing that PKC tolerates a "turn motif" mutation without disrupting catalytic activity (i.e., PKC-T638A is catalytically active) do not necessarily undermine this conclusion; apparently compensatory phosphorylations in the vicinity of the TA mutations can functionally substitute for the turn motif phosphorylation (emphasizing that some single residue mutations lead to uninformative phenotypes; Ref. 49).
Apart from its role to maintain the enzyme in a conformation that is favorable for catalysis, COOH-terminal phosphorylations have been implicated as mechanisms that control PKC binding to proteins or membranes. PKC isoforms (and other AGC kinases such as AKT and PKA) interact via their COOH terminus with both PDK-1 and the heat shock protein HSP70 (60). PDK-1 binds unphosphorylated PKC and leads to maturation of the nascent enzyme, whereas HSP70 binding to the dephosphorylated turn motif protects PKCβII from degradation. In keeping with the general notion that HSP70 preferentially binds hydrophobic residues, recent studies implicate an invariant Leu immediately preceding the turn motif phosphorylation site in HSP70 binding (61). Maneuvers that disrupt PKCβII-HSP70 interactions facilitate PKCβII dephosphorylation and ubiquitination and lead to the accumulation of PKCβII in the detergent-insoluble cell fraction (i.e., prevent PKCβII downregulation). PKC-HSP70 interactions may be particularly important in cancer, where high levels of HSP70 expression would prevent activation-dependent PKC dephosphorylation/downregulation.
Hydrophobic motif autophosphorylations also have been viewed as a mechanism that regulates cPKC binding to membranes. As noted in section IB, PKC and PKCβ translocation to the plasma membrane can be transient, and followed by subsequent translocation to a perinuclear compartment; hydrophobic motif autophosphorylation has emerged as a mechanism that regulates the release of PKC and PKCβII from the plasma membranes (16, 17, 55, 56, 94). This mechanism appears to be particularly important for PKC, which anchors to DAG-containing membranes only when it harbors an alanine substitution at its autophosphorylation sites or it is catalytically inactive; DAG does not drive WT-PKC to membranes (205). These results have been taken as evidence that stoichiometric PKC autophosphorylation at the hydrophobic motif can tonically inhibit PKC actions at membranes under some conditions.
Finally, while most studies have focused on the kinases that phosphorylate PKCs, a ceramide-activated protein phosphatase (tentatively identified as PP1) is reported to dephosphorylate PKC/PKCβII at their activation loop sites (97). Other phosphatase mechanisms undoubtedly regulate PKC phosphorylations under many physiologically relevant conditions, but have largely been ignored in the literature.
B. nPKC Serine/Threonine Phosphorylations
Although nPKC priming phosphorylations were initially considered to follow the mechanisms described for cPKC isoforms, closer inspection exposed three notable differences: 1) PKC is unique among PKC family members in its ability to function as a kinase even without activation loop (Thr505) phosphorylation; the closely related nPKC isoform and other cPKC and aPKC isoforms are catalytically inactive without activation loop phosphorylation (121). 2) Some nPKC phosphorylations are dynamically regulated (and not constitutive) phosphorylations (173). 3) nPKC turn and hydrophobic motif phosphorylations have variably been characterized as autophosphorylation and transphosphorylation mechanisms (depending on the isoform and cell context). The text that follows elaborates further on these three aspects of nPKC regulation and function.
1. The molecular determinants of PKC activity: activation loop phosphorylation versus other mechanisms
Early studies from Stempka et al. (204) focused on E500, showing that this acidic residue in PKC's activation loop assumes the role of the activation loop phospho-Thr in cPKCs (Fig. 5). However, Liu et al. (120) recently identified another molecular feature of PKC that allows for activity without activation loop phosphorylation. In attempting to explain the fact that PKC is catalytically competent without activation loop phosphorylation, but the closely related PKC is not, these investigators noted that residues 320–345 of PKC (NH2 terminal to the catalytic domain and outside of the conserved catalytic core) models to an A-helix in PKA that spans the surface of both lobes of the catalytic core structure and is conserved in a number of other protein kinases (66, 74, 216; Fig. 5B). Trp30 and Phe26 in PKA (corresponding to Trp336 and Tyr332 in PKC) fill a deep hydrophobic pocket between the two lobes of the kinase domain; these residues participate in intramolecular interactions that stabilize the PKA structure. The PKC A-helix models as a structure that binds directly to the activation loop through hydrophobic interactions involving Tyr332 and three aromatic residues in or near the PKC activation loop, namely, Ile497, Phe498, and Phe525. These residues are not found in PKA or PKC; although these residues are found individually in certain other PKC isoforms (i.e., Phe498 is conserved in PKC, Phe525 is conserved in PKC, and Ile497 is conserved in PKCβ and other nPKC isoforms), PKC is the only enzyme that contains all four structural determinants. This hydrophobic stack functionally substitutes for activation loop Thr505 phosphorylation as a mechanism to generate a catalytically competent enzyme. These results suggest that PKC is equipped with a unique mechanism for activation loop stabilization that is not available to other PKC isoforms. However, PKC's substrate specificity differs somewhat (particularly toward substrates with basic residues in positions P-4 and P-5) depending on whether it is stabilized through an activation loop phosphorylation or this hydrophobic stack. As a result, the PKC-T505A mutant mimics only some WT-PKC responses in cells; it triggers apoptosis, but it does not mimic the effect of WT-PKC to activate NFB or AP-1 reporter constructs in Jurkat T cells (120). Of note, Cheng et al. (30) recently identified a role for PKC-T505 phosphorylation in the formyl-methionyl-leucyl-phenylalanine pathway leading to NADPH activation in phagocytes, showing that a single T505A substitution abrogates PKC phosphorylation of p47phox (but not other substrates such as histone). These results are consistent with our recent studies showing that WT-PKC and PKC-T505A differ with respect to the phosphorylation of individual sites on the myofibrillar protein cardiac troponin I (206), which are described in greater detail in section VC. The notion that activation loop phosphorylation regulates PKC substrate specificity (rather than absolute PKC activity) could underlie previous discrepancies in the literature regarding the role of Thr505 phosphorylation in the control of PKC catalytic function (106, 173, 203). Studies to date have relied heavily on in vitro kinase assays with specific "model" substrates and would be profoundly influenced by the specific assay conditions, including the choice of substrate (see sect. VIIIC). Finally, these results underscore the importance of coordinate translocation events (that regulate PKC's intracellular localization) and phosphorylation events that "fine tune" PKC's enzymology in cells.
2. The controls of nPKC activation loop phosphorylation
The original studies from the Parker laboratory combined in vitro and overexpression approaches to characterize PDK-1 as a PKC binding partner and PKC activation loop kinase (106). Subsequent studies from the Newton laboratory identified a similar effect of PDK-1 to act as a PKC activation loop kinase, showing that PDK-1 stimulates PKC activation loop (T566) phosphorylation and triggers subsequent PKC autophosphorylation at the COOH-terminal turn and hydrophobic motif sites (24). This model is analogous to the model set forth for cPKC isoforms. In contrast, we recently identified a different mechanism that contributes to the dynamic control of PKC activation loop (T505) phosphorylation (170). We showed that PKC retains little-to-no T505 phosphorylation in resting cardiomyocyte cultures; PKC-T505 phosphorylation is induced by G protein-coupled receptor agonists that promote DAG accumulation (i.e., the 1-AR agonist norepinephrine, endothelin, and PGF2) or by PMA through a mechanism that requires nPKC activity. These results implicate either a PKC autocatalytic mechanism or PKC phosphorylation in trans by another nPKC isoform (such as PKC) as the mechanisms for the dynamic agonist-dependent increase in PKC-T505 phosphorylation; PDK-1 does not contribute to this process. With regard to a potential PKC autophosphorylation mechanism, it is interesting to note that PKC and PKC activation loop phosphorylation sites reside in PKC consensus phosphorylation motifs (i.e., RAST505F and KTNT538F in PKC and PKC, respectively; Fig. 5A). Other PKC isoforms lack a positively charged residue at the –3 position. Moreover, while early in vitro studies from Parker's laboratory did not detect PKC-T505 autophosphorylation, these studies used a bacterially expressed PKC preparation that retained only limited catalytic activity and would not detect a PKC activation loop autophosphorylation (106).
Studies using adenoviral-mediated PKC overexpression have recently exposed a novel form of PKC-PKC cross-talk, showing that PKC overexpression leads to a robust increase in PKC-T505 phosphorylation (without any changes in PDK-1 protein/activity) in cardiomyocytes and several other cell types (170). While these results could be construed as evidence that PKC acts as a direct PKC-T505 kinase, a more detailed analysis revealed that 1) PKC overexpression does not lead to an increase in PKC-T505 phosphorylation in cells treated with PP1 (a Src kinase inhibitor); 2) the PKC-dependent increase in PKC-T505 phosphorylation is not detected in SYF cells, that lack the major Src family kinases (Src, Yes, and Fyn) and display a defect in PKC-Tyr311/Tyr332 phosphorylation; and 3) the PKC-dependent increase in PKC-T505 phosphorylation is restored by Src reexpression (which restores PKC-Tyr311/Tyr332 phosphorylation) in the Src+ cell line (170). These results indicate that PKC promotes PKC-T505 phosphorylation via an indirect mechanism that requires Src activity (and PKC tyrosine phosphorylation, Fig. 7 A). In vitro kinase assays exposed the underlying mechanism, showing that PKC undergoes a T505 autophosphorylation reaction that is facilitated when assays are performed in the presence of active Src (under conditions leading to PKC-Tyr311/Tyr332 phosphorylation). Collectively, these results add a new dimension to models of PKC signaling, showing that Src is a physiologically relevant PKC-Tyr311/Tyr332 kinase in cells and that Src-dependent PKC tyrosine phosphorylation controls PKC-T505 autophosphorylation. According to this revised model of PKC signaling, PKC is uniquely positioned to sense signaling inputs from both Src and PKC pathways. However, the mechanism(s) linking PKC signaling to increased PKC tyrosine (Tyr311/Tyr332) phosphorylation remains uncertain. Studies to date show that PKC overexpression does not lead to gross changes in the abundance or activity of Src family kinases; studies to determine whether PKC regulates PKC tyrosine phosphorylation by inhibiting a PKC-targeted phosphatase are ongoing.
|
nPKCs also undergo COOH-terminal phosphorylations at conserved turn and hydrophobic motifs. nPKC COOH-terminal phosphorylations have been attributed to either autophosphorylation or transphosphorylation mechanisms (24, 152). Early studies from the Parker laboratory attributed PKC hydrophobic motif phosphorylation to the actions of a heterologous kinase complex comprised of mTOR and an atypical PKC isoform (152, 239). However, subsequent studies have identified a hydrophobic motif phosphorylation defect for KD-PKC and KD-PKC; this result is more consistent with a hydrophobic motif autophosphorylation (121). In contrast, KD-PKC and KD-PKC are recovered with detectable (albeit reduced) turn motif phosphorylation, suggesting that the turn motif is the preferred target for phosphorylation in trans (121).
No single model is sufficient to describe the effect of nPKC COOH-terminal phosphorylations on enzyme function. PKC is reported to require turn motif phosphorylation for full catalytic function, whereas PKC appears to require hydrophobic motif phosphorylation (rather than turn motif phosphorylation) for catalytic activity (24, 112, 121). The general consensus (based on structural models of PKA and PDK-1) is that the hydrophobic motif participates in an intramolecular interaction that stabilizes the enzyme in an optimal conformation for catalysis (121). However, the functional role of individual PKC priming phosphorylations has been difficult to resolve, in large part due to the fact that PKC mutants lacking phosphorylation at either the activation loop or the COOH terminus become targets of phosphatases. While the fully phosphorylated enzyme is relatively resistant to dephosphorylation by phosphatases (since the hydrophobic motif negative charge protects the activation loop from dephosphorylation, and the activation loop phosphorylation exerts a reciprocal effect to protect the hydrophobic motif from dephosphorylation) (16, 17), the PKC-S729A hydrophobic motif mutant displays an activation loop phosphorylation defect, and the PKC-T538A activation motif mutant displays a hydrophobic loop phosphorylation defect. Both of these secondary phosphorylation defects are reversed by treatment with a Ser/Thr phosphatase inhibitor (24, 121). These reciprocal regulatory controls render the analysis of PKC phosphorylation mechanisms quite challenging.
C. Kinase Domain Tyrosine Residues
There is a limited but generally consistent literature indicating that certain catalytic domain tyrosine residues (that are highly conserved across AGC kinase family members) influence enzyme activity. The initial studies implicated Tyr204 in PKA (corresponding to PKC-Tyr512) in intramolecular interactions that structure the catalytic pocket for phosphoryl transfer (232). While the cognate residue in PKC is phosphorylated in the context of oxidative or genotoxic stress, PKA tyrosine phosphorylation has never been considered. Rather, most studies have focused on PKC, which is tyrosine phosphorylated (including at Tyr512 and Tyr523) and activated in cells treated with H2O2. The Nishizuka laboratory has reported that single residue substitutions at Tyr512 or Tyr523 attenuate (and the combined Tyr512/Tyr523 mutation abrogates) H2O2-dependent PKC activation (albeit without completely blocking H2O2-dependent PKC tyrosine phosphorylation) (102, 103). The Kufe laboratory has also implicated PKC-Tyr512 phosphorylation in mechanisms that contribute to oxidative stress responses involving c-Abl, showing that H2O2 promotes PKC translocation and a local increase in PKC-Tyr512 phosphorylation in the mitochondrial compartment. In this case, PKC-Tyr512 phosphorylation is attributed to c-Abl (which also localizes and is activated via a PKC-dependent mechanism in mitochondria of H2O2-treated cells). This local PKC-Abl amplification loop leads to an increase in PKC activity which contributes to the mitochondrial death response (105, 207). While studies from the Kufe laboratory failed to detect c-Abl-dependent PKC-Tyr523 phosphorylation, aPKC phosphorylation at the equivalent tyrosine residue (PKC-Tyr428, PKC-Tyr421, sites that model to a position close to the active site) is reported to increase enzyme activity (162). The notion that PKC phosphorylation at highly conserved tyrosine residues in the activation loop might constitute an alternate (threonine phosphorylation-independent) activation mechanism for certain PKC isoforms (in particular PKC or aPKCs) requires further study. Finally, the Blumberg laboratory identified Tyr565, along with Tyr155 and Tyr52, as in vitro Lyn-dependent phosphorylation sites in PKC, although the functional importance of PKC-Tyr565 phosphorylation as a mechanism to alter PKC catalytic activity was not examined (and the functional significance of this event is uncertain, since other studies link Lyn activation in activated RBL-2H3 cells to PKC phosphorylation at Tyr52 in the C2 domain, and not Tyr565) (209).
D. Kinase Domain Features That Distinguish aPKCs From cPKC/nPKC Isoforms
aPKC isoforms are generally distinguished from phorbol ester-sensitive cPKC and nPKC isoforms on the basis of their truncated C1 domains. However, three rather striking differences between aPKC and phorbol ester-sensitive cPKC/nPKC kinase domains have been identified. These differences are likely to have important implications for the development of PKC isoform-specific therapeutics.
100-fold lower affinity for GF109203X (a competitive ATP inhibitor that acts by displacing ATP from this ATP binding pocket), relative to cPKC and nPKC isoforms (72). A tyrosine (GRGSYA) in the aPKC ATP binding loop represents a second structural feature that could impart signaling specificity; cPKC and nPKC isoforms contain a phenylalanine at this position (GRGSFG). Nucleotide binding loop tyrosine phosphorylations control the catalytic activity of certain cyclin-dependent kinases (which are inactive when tyrosine phosphorylated and activated by cellular phosphatases prior to the initiation of mitosis, Ref. 146) and Bcr-Abl (169, 186). Similarly, nerve growth factor (NGF) activates PKC via a mechanism that involves the activation of Src, enhanced PKC-Src complex formation (via an interaction mapped to the Src-SH3 domain and a proline-rich 98VFPSIPEQPGMPCPGE114 sequence just NH2 terminal to the PKC regulatory domain pseudosubstrate domain), and Src-dependent PKC-Y256 phosphorylation. The functional importance of this phosphorylation is suggested by the further observation that Y256 phosphorylation increases PKC binding to importin-β (presumably as a result of a phosphorylation-dependent conformational change that exposes an otherwise hidden arginine-rich functional NLS in the aPKC C1 domain) and leads to enhanced PKC entry into the nucleus (155, 221). NGF also increases Src-dependent PKC phosphorylation at two other tyrosine residues, namely, Tyr271 (which is at the –3 position relative to the invariant Lysine) and Tyr325 (which is +2 to the kinase domain gatekeeper residue) (224). A single YF mutation at Tyr325 (but not Tyr256 or Tyr271) reduces Src-dependent PKC activation and NGF-dependent survival in PC12 cells (224). While a tyrosine at the +2 position relative to the gatekeeper residue is conserved in many kinases, a general role for regulatory phosphorylations at this site in other kinases has not been considered. - and β-phosphates of ATP (to orient ATP for catalysis); it also participates in intramolecular interactions that stabilize the catalytically active conformation of the kinase. Single residue substitutions at Lys72 of PKA (including mutations to Arg or His that conserved charge, mutations to Met that conserve approximate size, or mutations to Ala) result in nonproductive ATP binding modes and a catalytically inactive enzyme (84, 85). However, PKC tolerates an LysArg replacement at this site; the PKC-K274R mutant binds ATP, is catalytically active, and displays an affinity for GF109203X that is identical to the WT enzyme (194). PKC activity is disrupted by a K274W substitution. These results provide tentative evidence that the ATP binding pockets of aPKCs are distinctive (relative to other protein kinases) and that these unique structural features might provide the basis for the development of highly specific aPKC isoform inhibitors that do not inhibit other PKCs or unrelated protein kinases. | V. THE HINGE REGION |
|---|
|
TopPreviousNextReferences |
|---|
A. Caspase Cleavage at the Hinge Region
PKC, PKC, PKC, and PKC undergo caspase-dependent cleavage in response to a range of apoptogenic stimuli; the atypical PKC and - isoforms have no sequence homology with the PKC hinge region, lack caspase cleavage sites, and do not appear to be regulated in this manner (58). Hinge region cleavage by caspase results in the release of a catalytic domain fragment that is freed from autoinhibitory regulatory domain constraints. While this has been viewed as a model to activate PKC, this model is valid only if kinase domains are intrinsically catalytically competent (i.e., endowed with all of the structural determinants required for catalytic activity); most studies that examine cleavage-dependent PKC activation mechanisms have ignored a potential requirement for activation loop transphosphorylation. In fact, as noted in section IVB1, this assumption is justified for PKC, which is active without activation loop phosphorylation, although differences in the enzymology of full-length PKC (which is inhibited by sphingosine) and the freed PKC catalytic domain (which acts as a sphingosine-dependent kinase to phosphorylate 14-3-3 proteins) have been noted (73). The freed PKC catalytic domain is recovered as an active kinase, suggesting that activation loop phosphorylation (which is required for PKC activity) is a constitutive modification that is retained following caspase-dependent cleavage. In contrast, two laboratories have reported that the free catalytic domain of PKC is catalytically inactive (58, 188). This result was not predicted based on a sequence comparison with PKC. As noted in section IVB1, an acidic Glu500 immediately preceding the PDK-1 phosphorylation motif in PKC has been viewed as a structural feature that might functionally substitute for activation loop phosphorylation (leading to autonomous PKC activity without Thr505 phosphorylation). Atypical PKCs (such as PKC, as well as PKC, but not PKC and other PKC isoforms) also contain acidic aspartyl residues at this position. PKC also has a phosphomimetic glutamate at the conserved hydrophobic motif autophosphorylation site, in theory making it the PKC isoform that is most favorably configured to be constitutively active without phosphorylation. However, the recent evidence that phosphatase treatment, T410A substitution, or mutations at the PDK-1 docking motif generate a catalytically inactive enzyme argues strongly that both full-length PKC and the freed PKC kinase domain require activation loop Thr410 phosphorylation for catalytic activity (188).
Proteolytic PKC activation by caspases (that contribute to proapoptotic responses) is a prominent mechanism in many, but not all, cell types. Recent studies expose alternative splicing mechanisms for both human and rodent PKC that increase PKC V3 domain structural diversity by introducing inserts that disrupt the caspase-3 cleavage site [at DIL
DNNGTY332 in mouse PKC (177) and DMQDNSGTY334 in human PKC (86)], prevent proteolytic PKC activation, and protect cells from proapoptotic stimuli. Studies exploring the functional importance of V3 domain alternative splicing mechanisms are confined to neurons, where the differentiation factor retinoic acid regulates PKC alternative splicing. This leads to a shift in the relative abundance of full-length PKC versus the PKC COOH-terminal catalytic fragment (which exert diametrically opposite effects to prevent or induce cellular apoptosis, respectively) leading to important changes in neurogenesis.
The PKC-Asp294Gly mutation is found in a subpopulation of particularly aggressive pituitary tumors, although the precise role of this mutation in tumor progression remains uncertain (161, 213). Studies to date have focused on a trafficking defect. WT-PKC does not translocate to the surface membrane in isolated cells pituitary GH3B6 cells (i.e., cells that lack cell-cell contacts); G protein-coupled receptor agonists and PMA direct WT-PKC to cell-cell contacts, but not to the remainder of the surface membrane. However, the PKC-D294G mutant (which exhibits grossly normal catalytic activity) translocates to the entire surface membrane of both single and apposed cells; the PKC-D294G mutant is not confined to cell-cell contacts. This phenotype suggests that the PKC-V3 region is important for binding to specialized membranes (161).
C. PKC-Tyr311 and -Tyr332 Phosphorylation
The functional consequences of PKC-Tyr311 and/or -Tyr332 phosphorylation are just beginning to emerge, largely because previous literature had focused on the role of PKC tyrosine phosphorylation in general (and not necessarily Tyr311 or Tyr332 phosphorylation) and the results were inconclusive; tyrosine phosphorylation was variably implicated as a mechanism that increases, decreases, or does not change PKC catalytic activity. The absence of any consensus in the literature is presumed to reflect the presence of many tyrosine residues that are targets for independently regulated phosphorylation events throughout PKC's structure. The precise configuration of tyrosines phosphorylated on PKC varies according to the inciting stimulus and likely dictates the functional consequences with respect to enzyme activity. In general, the highly conserved tyrosines in or near the activation loop (Tyr512 and perhaps Tyr523) have been implicated in the control of catalytic function (see sect. IVC), whereas tyrosine phosphorylation in the regulatory region (Tyr52, Tyr64, Tyr155, Tyr187) appears to be more important for PKC-dependent changes in gene expression and/or growth/apoptosis responses; regulatory domain phosphorylations generally have not been linked to changes in PKC kinase activity.
Our recent studies have focused on PKC-Tyr311 and -Tyr332 phosphorylation in cardiomyocytes; two distinct mechanisms have been identified. We showed that H2O2 activates Src family kinases (SFKs, Src and the related Fyn, Lyn, and Yes kinases) and induces a global increase in PKC phosphorylation at Tyr311 and Tyr332 in both soluble and particulate cellular compartments; H2O2-dependent PKC-Tyr311/Tyr332 phosphorylation is via a PP1-sensitive pathway, suggesting a role for Src or a related SFK (172). In contrast, PMA promotes PKC tyrosine phosphorylation by delivering PKC to caveolae (a SFK-enriched membrane fraction); PMA-dependent PKC-Tyr311 phosphorylation is confined to the caveolae fraction and disrupted by cyclodextrin (a cholesterol-binding agent that undermines caveolae structural integrity). Of note, PMA-dependent PKC-Tyr311 phosphorylation also is via a PP1-sensitive mechanism, but PMA does not increase Src family kinase activity (171, 172). In vitro kinase assays suggest a possible mechanism for the PMA-dependent increase in PKC tyrosine phosphorylation, showing that Src preferentially phosphorylates the active conformation of PKC (i.e., PMA induces a conformational change that renders PKC a better substrate for Src kinases, that constitutively localize to caveolae membranes; Ref. 172). However, the identity of the PMA-activated (PP1-sensitive) kinase that phosphorylates PKC at Tyr311, but not Tyr332, remains uncertain. While studies in SYF cells (a continuous fibroblast cell line generated from the embryos of mice lacking the three major SFKs, Src, Yes, and Fyn) and Src+ cells (a SYF cell derivative engineered to overexpress Src) provide unambiguous evidence that Src is required for PKC-Tyr311 and -Tyr332 phosphorylation under certain stimulatory conditions (171) (and Tyr311 and Tyr332 appear to be the major in vivo PKC phosphorylation sites in many H2O2-treated cell types), a role for Src (and related SFKs) in the PMA-dependent pathway that leads to PKC phosphorylation at Tyr311 (but not Tyr332) in cardiomyocytes caveolae is not obvious. In vitro kinase assays followed by immunoblot analysis with phosphosite specific antibodies or peptide sequencing approaches identify similar effects of other SFKs, such as Fyn, Lyn, and Yes to phosphorylate PKC at both Tyr311 and Tyr332 (206). Other tyrosine kinases that might signal downstream from Src (i.e., act in a PP1-sensitive manner) and might be localized to caveolae (including PDGFRs, FAK, and JAK2) exhibit little to no PKC-Tyr311/Tyr332 kinase activity (171). Rather, our recent studies implicate c-Abl as a selective PKC-Tyr311 kinase; c-Abl does not phosphorylate PKC at Tyr332 (171). However, c-Abl is not detected in cardiomyocyte caveolae, and pharmacological studies with Gleevec (a very potent c-Abl inhibitor) establish that PMA-dependent PKC-Tyr311 phosphorylation does not require c-Abl activity (although c-Abl does appear to contribute to H2O2-dependent PKC-Tyr311 phosphorylation, Ref. 171). The molecular components of the PMA-dependent PP1-sensitive PKC-Tyr311 phosphorylation pathway in cardiomyocyte caveolae remain the focus of ongoing studies. Finally, it is important to note that G protein-coupled receptor agonists (such as norepinephrine and endothelin) do not increase PKC-Tyr311 phosphorylation; these agonists also fail to promote PKC translocation to caveolae (171). This cannot be attributed to differences in PKC activation by PMA and DAG (the endogenous lipid cofactor), since DAG analogs support Src- (or c-Abl-) dependent PKC tyrosine phosphorylation in vitro and DAG mimics the effect of PMA to recruit PKC to caveolae and increase PKC-Tyr311 (and Thr505) phosphorylation in cardiomyocytes. The observation that DAG analogs effectively substitute for PMA both in vivo and in vitro argues that 1-ARs do not increase PKC tyrosine phosphorylation because they do not promote DAG accumulation in caveolae membranes, either because the density of 1-ARs or their downstream signaling partners is limiting in cardiomyocyte caveolae (171).
Some studies implicate PKC phosphorylation at Tyr332 (and perhaps also Tyr311, sites that flank a caspase cleavage site) as a mechanism that facilitates PKC activation via caspase-dependent cleavage in cells undergoing apoptosis (125). However, insofar as cleaved forms of PKC are not convincingly identified in H2O2-treated cardiomyocyte cultures (unpublished data) and certain other cellular contexts, studies of hinge region tyrosine phosphorylation have focused on other cellular processes. Early studies established that Tyr311/Tyr332-phosphorylated PKC is recovered as a lipid-independent enzyme in both the soluble and particulate fraction of H2O2-treated cells (including cardiomyocytes); this lipid-independent form of PKC is predicted to mediate PKC responses throughout the cell, not just on lipid membranes (102, 103, 172). However, recent studies expose a considerably more elaborate role for Src (and hinge region tyrosine phosphorylation) in the control of PKC activity. Building on the recent evidence that Src (and PKC-Tyr311/Tyr332 phosphorylation) increases PKC-Thr505 autophosphorylation (170; as noted in sect. IVB2), we showed that Src also regulates PKC-dependent phosphorylation of a physiologically important cardiac substrate, namely, cardiac troponin I (cTnI). cTnI is the "inhibitory" subunit of the troponin complex that contributes to Ca2+-dependent regulation of myofilament function in the heart (Fig. 8). Our recent studies establish that PKC phosphorylates cTnI at Ser23/Ser24 (a site traditionally viewed as a PKA target) when it is allosterically activated by PMA; functional studies on skinned muscle fibers show that lipid cofactor-activated PKC sensitizes the myofibril to submaximal Ca2+, but has no significant effect on maximum Ca2+-activated tension (the predicted effect of cTnI-Ser23/Ser24 phosphorylation). However, PKC acquires the ability to also phosphorylate cTnI at Thr144 (in addition to Ser23/Ser24) when it is tyrosine phosphorylated by Src; functionally, this abrogates calcium sensitization (the effect of selective cTnI phosphorylation at S23/S24) and leads to a decrease in maximum Ca2+-activated tension, the predicted effect of cTnI-Thr144 phosphorylation (based on previous literature, Ref. 22). A mutagenesis approach was used to map the structural determinants for Src-dependent changes in PKC substrate specificity. These studies showed that the Src-dependent change in PKC substrate specificity (enabling PKC to act as a cTnI-T144 kinase) is abrogated by either a YF substitution at Tyr311 (but not Tyr332) or a TA substitution at Thr505; Y311F and T505A substitutions had no effect on cTnI-S23/S24 phosphorylation by PKC in the presence of PMA. These results identify a role for Src-dependent PKC-Tyr311 phosphorylation and PKC-Thr505 autophosphorylation as novel regulators of PKC's substrate specificity, leading to enhanced PKC activity toward only selected sites on cTnI and a functionally important change in contractile function. Of note, these results conform to recent observations by Lui et al. (120) showing that PKC acquires activity toward substrates with basic residues at positions P-4 and/or P-5 when phosphorylated at Thr505. Wild-type PKC (which is Thr505-phosphorylated in assays with Src) phosphorylates cTnI at KFKRPT141 (a site that contains a basic residue at position P-5 relative to the phosphorylation sites), whereas the PKC-T505A mutant does not; its actions are confined to PAPIRRRS23S24.
|
's interactions with other signaling proteins. Tyr332 is one of two tyrosines in PKC with a +3 position Ile that conforms to a consensus binding sequence for the SH2 domain of Shc, an adapter protein that nucleates signaling to the MAPK cascade. PKC-Tyr332 phosphorylation in RBL-2H3 cells leads to the formation of PKC-Shc complexes and a physiologically important indirect interaction between PKC and SHIP [an SH2-domain-containing inositol 5'-phosphatase that also binds Shc, dephosphorylates PI(3,4,5)P3 to PI(3,4)P2, and provides a mechanism to negatively regulate AKT phosphorylation] (110, 191). Our recent studies indicate that PKC-Shc complexes accumulate in a detergent-insoluble cytoskeletal fraction (that is enriched in intermediate filament proteins such as vimentin, vinculin, and desmin) in H2O2-treated cardiomyocytes. WT-PKC overexpression leads to an increase in H2O2-dependent Shc localization to this fraction, whereas KD-PKC (which constitutively localizes to the cytoskeletal fraction) leads to increased Shc localization to the cytoskeleton, even without an oxidative stress stimulus. These results expose a kinase-independent role for PKC to regulate the subcellular localization of Shc (and potentially other binding partners). While PKC accumulates in the cytoskeleton of H2O2-treated cardiomyocytes as a Tyr332-phosphorylated protein (and KD-PKC is constitutively Tyr332-phosphorylated in this fraction), the role of PKC-Tyr332 phosphorylation in this process in cardiomyocytes is not convincing. Pharmacological inhibitors that prevent PKC tyrosine phosphorylation do not disrupt PKC-Shc interactions or prevent PKC-dependent Shc localization to the cytoskeletal fraction in H2O2-treated cardiomyocytes. The molecular determinants of PKC-Shc interactions are the focus of ongoing studies. | VI. THE V5 DOMAIN |
|---|
|
TopPreviousNextReferences |
|---|
A. PKCβ V5 Domain Splice Variants With Distinct Subcellular Targeting and Signaling Functions
PKCβ is expressed as differentially spliced versions of the same gene (termed PKCβI and PKCβII) that differ only at their COOH-terminal V5 regions. PKCβI and PKCβII are expressed in a tissue-specific and developmentally regulated manner (26). Endogenous PKCβ isoforms target to distinct subcellular compartments (both at rest and following activation) and have been linked to distinct cellular functions (in some cases, even in a single cell type). For example, individual PKCβ isoforms exert functionally opposing actions in A10 vascular smooth muscle cells. The effects of PKCβI to stimulate and PKCβII to inhibit A10 vascular smooth muscle growth constitute perhaps the most convincing evidence that PKC isoforms can decode second messenger signals in a highly specialized manner as a result of subtle differences in V5 domain structures (228).
Both native and heterologously overexpressed PKCβI and PKCβII exhibit distinct subcellular localization patterns. In cardiomyocytes, endogenous PKCβI localizes to the cytosol and perinuclear region under basal conditions and translocates to the nucleus following treatment with PMA, whereas native PKCβII decorates fibrillar cytoskeletal structures at rest and translocates to the cell periphery and the perinuclear region (where it colocalizes with the PKC anchoring protein RACK1) following treatment with PMA (44, 167). In PMA-treated NIH3T3 fibroblasts, both PKCβI and PKCβII are detected at membrane ruffles, but only PKCβII (which contains a V5 domain actin binding site somewhat homologous with the actin binding site of troponin I) accumulates in the cytoskeleton at actin-rich microfilaments (15, 68; Fig. 6). PKCβII tethered to cytoskeletal F-actin displays increased autophosphorylation (including in the absence of lipid cofactors), enhanced trans-phosphorylation of selected physiological substrates such as vimentin (but not necessarily all substrates, suggesting a change in substrate specificity), and resistance to PMA-dependent downregulation (15). As noted is previous sections, PMA transiently/reversibly translocates PKCβI and PKCβII to the plasma membrane, but only PKCβII translocates in a more sustained (irreversible) manner to a juxtanuclear site containing a subset of recycling endosomes during chronic agonist exposure (11).
PKCβI and PKCβII display distinct oscillation patterns (between the cytosol and membranes) in response to metabotropic glutamate receptor-1a activation (i.e., a single stimulus) in HEK293 cells (6, 68). Here, two nonconserved residues in PKCβII's V5 domain (Asn625 and Lys668, that lie within two of the three V5 domain sequences that have been implicated as RACK1-binding motifs; Refs. 6, 68, 200) were mapped as structural determinants of the distinct translocation patterns. Single N625G or K668G substitutions at either site convert PKCβII to an enzyme that translocates in a PKCβI-like manner (6).
RACK1 anchors PKCβII (but not PKCβI) to the perinuclear region; a PKCβI selective RACK protein has not yet been identified. While RACK1 binding sites were initially mapped to the PKCβ C2 domain, C2 domain RACK1 binding sites (which are common to PKCβI and PKCβII) do not explain the in vivo specificity of RACK1 for PKCβII. Rather, RACK1-binding specificity has been attributed to protein-protein interaction motifs in the V5 domain that are unique to PKCβII (621ACGRNAE627, 645QEVIRN650, and 660SFVNSEFLKPEVKS673) and not found in PKCβI. A peptide based on the unique RACK1 binding sequence in PKCβII (645QEVIRN650) acts as PKCβII-selective translocation inhibitor when introduced into permeabilized neonatal cardiomyocyte cultures; similarly, a peptide based on the putative PKCβI-RACK binding site (the unique 645KLFIMN650 sequence in PKCβI) selectively inhibits PKCβI translocation. The observation that PMA-dependent cardiomyocyte hypertrophy is inhibited by either the PKCβI or the PKCβII translocation inhibitor peptides suggests that both PKCβ isoforms contribute to cardiac growth responses (200).
Other studies have exploited a chimeric approach to show that the COOH-terminal 13 amino acids of PKCβII are sufficient to confer a "PKCβII-specific" function (namely localization to the nucleus and lamin B phosphorylation) to PKC (65). While these results are consistent with the notion that the PKCβII V5 region contains the molecular determinants for nuclear localization, studies using chimeric constructs must be interpreted with caution given the growing recognition that the phosphorylated hydrophobic motif forms stabilizing intramolecular contacts with other regions of the enzyme (including the C2 domain and the catalytic core) and that cooperative intramolecular interactions fulfill a crucial function to regulate affinity for substrate and cofactors as well as calcium-dependent binding to acidic membranes (95). Foreign V5 domains that cannot participate in cooperative intramolecular interactions might not necessarily produce informative phenotypes.
B. The V5 Domain and PKC Catalytic Function
Yeong et al. (233) recently published surprising evidence that the very distal portion of the V5 domain (COOH terminal to the hydrophobic motif phosphorylation site, that is absent in PKA) is critical for PKC catalytic activity and function in cells (233). These investigators used a deletion approach to show that a single residue truncation at the extreme COOH terminus leads to a 60% reduction in enzyme activity (without any activation loop phosphorylation defect); truncation of the last 10 amino acids results in a PKC mutant that lacks activation loop phosphorylation and is essentially catalytically inactive. A similar seven-residue COOH-terminal truncation abrogates the catalytic activity of PKC (in this case, without fully blocking activation loop phosphorylation, Ref. 238). In each case, modeling studies identified an intramolecular interaction between the V5 domain and the N-lobe of the kinase that structures the ATP-binding pocket and influences enzyme activity. Further studies showed that an antibody directed against the PKC extreme COOH terminus immunoprecipitates PKC protein, but relatively little PKC activity; in contrast, an antibody directed against an NH2-terminal determinant (in this case a tag) immunoprecipitates catalytically active PKC. These results have been interpreted as evidence that protein-protein interactions involving the PKC extreme COOH terminus might prevent V5 domain interactions with the catalytic pocket (i.e., mimic the effect of a truncation) and inhibit catalytic activity (233). The implications of these results to the interpretation of the PKC literature (which has relied heavily on immune kinase assays performed with antibodies directed against PKC-V5 domain epitopes) and the full functional significance of PKC V5 domain epitopes as determinant of enzyme activity (that could be targeted to generate isoform-specific PKC antagonists) require further study. Finally, it is worth noting that the PKC extreme COOH terminus is the only PKC isoform that ends in a COOH-terminal PDZ (PSD-95, disheveled and ZO-1) domain consensus binding motif (QSAV). Staudinger et al. (199) have demonstrated that PKC interacts (through this COOH-terminal motif) with the PDZ domain-containing protein PICK1. PICK1 self-associates and forms oligomers with other PDZ domain containing proteins at membranes, providing a rationale to consider PICK1 as a scaffold that localizes PKC with other signaling partners at specialized membranes.
C. The V5 Domain and PLD Activation
The PKC V5 domain has been implicated in the activation of PLD. PKC activates PLD through a protein-protein interaction (i.e., a kinase-independent mechanism); while PLD is a target for PKC-dependent phosphorylation, this is an inhibitory mechanism that reduces PLD activity (76). Recent literature suggests that PLD does not bind to a single region of PKC; rather, the PKC-PLD interaction involves many points of contact between these proteins (76, 185). Nevertheless, the PKC-V5 domain appears to be particularly critical for in vivo PLD activation. A COOH-terminal 10-amino acid deletion or a single V5 domain substitution at Phe663 (10 residues from the COOH terminus) fully abrogates in vivo PKC-dependent PLD activation (76). PKCβII (which shares a high level of V5 domain structural homology with PKC) also activates PLD, whereas PKCβI (with a structurally more divergent V5 domain) does not.
D. V5 Domain and Nuclear Localization Signals
In some cells, PKC localizes to the nucleus early in apoptosis. The structural requirements for PKC entry into the nucleus have been mapped to six basic amino acid residues that reside in a functional NLS in the COOH terminus (611KRKVEPPFKPKVK623, Fig. 6) (43). While many of these basic residues are conserved in other cPKC and nPKC isoforms, their role in the nuclear localization of other PKCs has not been examined. The PKC NLS directs rapid nuclear import of full-length PKC. Studies with chimeric PKCs show that the PKC V5 domain contains all of the molecular determinants required for nuclear localization; a chimeric PKC-V5 construct accumulates in the nucleus and induces apoptosis, whereas PKC itself does not accumulate in the nucleus under identical conditions (43).
E. V5 Domain Tyr Phosphorylation
A single study identifies a tyrosine phosphorylation of a COOH-terminal site on PKC (Tyr658) and PKCβI (Tyr662) that is mediated by the non-receptor tyrosine kinase Syk (and not Lyn or BtK) and requires prior phosphorylation of adjacent hydrophobic motif serine residues (S657 in PKC and S661 in PKCβI) (92). Once phosphorylated, this tyrosine residue docks the SH2 domain of Grb2, leading to Grb2/SOS binding and the activation of the Ras/ERK pathway. In theory, PKC and PKC (which also contain tyrosine residues at the +1 position following the hydrophobic motif phosphorylation site) also might nucleate a Grb2/SOS/Ras activation complex through this mechanism, whereas PKCβII and PKC lack tyrosines at this position. The importance of this COOH-terminal structural feature as a mechanism that might underlie the distinct signaling properties of individual PKC isoforms has not been explored in any subsequent studies.
| VII. NONTRADITIONAL PKC ACTIVATION MECHANISMS |
|---|
|
TopPreviousNextReferences |
|---|
Several PKCs are cleaved by caspase during apoptosis. PKC cleavage in cells subjected to serum starvation, chemotherapeutic agents, or tumor necrosis factor (TNF)- has generally been attributed to caspase 3 and mapped to SSPD383G in the hinge region (although caspase 7 can substitute for caspase 3 in MCF-7 cells that lack caspase 3 activity, Refs. 9, 150). PKC exerts a dichotomous role on cell function. Full-length PKC prevents the proapoptotic effects of TNF-, whereas the freed PKC catalytic fragment (that is generated in cells treated with TNF-) promotes apoptosis. This form of apoptosis is attenuated by WT-PKC overexpression and completely abrogated by overexpression of the caspase-insensitive PKC-D383A mutant (9, 150).
PKC also regulates apoptosis in a cell- and stimulus-specific manner. PKC contributes to the proapoptotic actions of etoposide, UV and -irradiation via a mechanism that typically involves the cleavage of PKC in the hinge region by caspase 3 and the generation of a 40-kDa catalytic domain fragment of PKC that is a constitutively active (phospholipid-independent) enzyme, since it is freed from the autoinhibitory constraints imposed by the NH2-terminal regulatory domain. The freed PKC catalytic domain serves as both a marker and effector of apoptosis. The PKC catalytic domain lacks regulatory region membrane targeting modules; it accumulates in the nucleus through its NLS. Nuclear targeted catalytic domain PKC is sufficient to induce apoptosis in certain cell types (52, 135). There is some evidence that PKC cleavage by caspase and proapoptotic signaling responses are facilitated by PKC phosphorylation at Tyr64/Tyr187 or Tyr332 (depending on the model and inciting stimulus, Refs. 14, 124). However, PKC is also reported to protect glioma cells from the proapoptotic effects of TRAIL through a mechanism that involves TRAIL-dependent PKC-Tyr155 phosphorylation leading to PKC translocation to the endoplasmic reticulum, caspase-dependent PKC cleavage, and the activation of the cytoprotective enzyme AKT (149). These opposing roles for PKC in the apoptosis pathways induced by etoposide and TRAIL emphasize the challenges associated with efforts to expose the specific cellular actions of this enzyme.
Differences in the enzymology of the freed PKC catalytic domain fragment and full-length PKC also have been noted; the freed PKC catalytic domain fragment acts as a sphingosine-dependent kinase to phosphorylate 14-3-3 proteins, whereas full-length PKC is inhibited by sphingosine (73). These results could suggest that full-length PKC and the PKC catalytic domain fragment play distinct roles to phosphorylate distinct cellular targets at different stages of apoptosis. In support of this concept, p73β (a structural/functional homolog of p53 that interacts with c-Abl and activates transcription from p53 promoters, Ref. 163) and nuclear DNA-dependent protein kinase (an enzyme essential for the repair of double-stranded DNA breaks, Ref. 13) have been identified as nuclear PKC substrates that are preferentially phosphorylated by the freed PKC catalytic fragment. Other substrates that might contribute to PKC's nuclear actions include hRad9 (key component of the genotoxin-activated checkpoint signaling complex which also binds antiapoptosis Bcl-2 family proteins and mediates apoptotic responses to DNA damage when phosphorylated by PKC, Ref. 234), lamin B (a nuclear structural protein that is cleaved upon phosphorylation, leading to the disassembly of the nuclear lamina, Ref. 35), and c-Abl (a kinase activated by apoptotic stimuli that forms complexes with Lyn, DNA-PK and PKC in the nucleus).
PKC is cleaved at a DEVD354K site in the hinge region by caspase 3 in response to various agents that induce apoptosis (38). The catalytic fragment of PKC is an active enzyme; overexpression of the cleaved kinase-active (but not full-length PKC or the kinase-inactive PKC catalytic fragment) is sufficient to induce nuclear fragmentation and cell death.
B. Kinase-Independent Actions of Freed Regulatory Domains
PKC regulatory domains (RDs) are generally viewed as dominant-negative inhibitors of the full-length enzyme, since they are predicted to compete with the cognate full-length enzyme for docking proteins at sites of action. However, certain PKC-RDs mimic the actions of the full-length protein (i.e., certain cellular responses are mediated by PKC regulatory domain and are kinase independent). For example, PKC colocalizes through its RD with F-actin at the cortical cytoskeleton where it functions to induce neurite outgrowth in neuroblastoma cells and plays an important role in neuronal differentiation (118, 236). PKC and PKC localize via their RD-C1 motif to the Golgi where PKC regulates glycosaminoglycan sulfation and PKC induces apoptosis (108, 182).
C. PKC Regulation by Reactive Oxygen Species
While the focus of most studies in the literature has been on the effects of oxidative stress to activate Src family kinases and alter PKC signaling mechanisms through PKC tyrosine phosphorylation, PKCs are also direct targets for redox modifications (69). Mild oxidative stress promotes the oxidation of C1 domain cysteine residues, leading to the release of Zn ions, reduced autoinhibitory function, and cofactor-independent PKC activation; PKC activation through this mechanism is discussed in section IIC. In contrast, intense oxidative stress modifies reactive cysteines in the kinase domain and abrogates PKC activity.
D. PKC Regulation by Reactive Nitrogen Species
The canonical nitric oxide (NO) signaling pathway involves the activation of guanylyl cyclase and the formation of cGMP. However, recent studies have exposed an additional guanylyl cyclase-independent effect of reactive nitrogen species to modify a range of biologically important molecular targets, including proteins, lipids, and DNA. NO and NO-derived reactive nitrogen species such peroxynitrate (or ONOO–, which is formed when NO reacts with superoxide) react with reduced cysteines or tyrosines, forming cysteine S-nitrosothiols or 3-nitrotyrosines, respectively. These posttranslational modifications have been linked to changes in the function of a variety of cellular proteins. Insofar as NO and PKCs share many signaling responses, including in the heart where both NO and certain PKCs have been implicated in cardioprotection, it was perhaps inevitable that there would be interest in a possible role of PKCs as NO targets (7). Studies to date have focused on PKC tyrosine nitration; PKC modification through S-nitrosylation has not yet been considered.
Knapp et al. (99) reported that high concentrations of ONOO– (100 µM) lead to the tyrosine nitration of PKC and PKCβII. These investigators reported that low ONOO– concentrations (1 µM, which does not promote PKC tyrosine nitration) increase PKC activity via a redox-dependent mechanism, whereas high ONOO– concentrations inhibit cofactor-dependent PKC, PKCβII, PKC, and PKC activities (99). However, high ONOO– concentrations also have been linked to increased intracellular protease activity and proteolytic activation of PKC (which is tyrosine nitrated under these conditions) in other studies (25).
PKC nitration has been reported to increase PKC signaling by enhancing PKC-protein complex formation. There is evidence that NO donors increase PKC tyrosine nitration and PKC binding to its anchoring protein RACK2 (or β'-COP, without changing the availability of RACK2 in membranes), leading to increased PKC protein and activity in the particulate fraction of rabbit cardiomyocytes (7). Protein nitration also has been identified as a PKC activation mechanism in substantia nigra-derived SN4741 dopaminergic cells, where sodium nitroprusside (SNP) promotes PKC nitration, PKC activation, enhanced PKC-p53 complex formation, and p53 phosphorylation at Ser15 (a residue adjacent to the p53-MDM2 binding site); SNP does not promote p53 phosphorylation at other serine residues (107). An effect of p53-S15 phosphorylation to disrupt ubiquitin-dependent p53 degradation (by preventing MDM2 binding) would increase apoptosis, and might have relevance to the pathophysiology of Parkinson's disease. However, it is important to note that the role of PKCs as targets for functionally important posttranslational modifications by NO-derived reactive nitrogen species remains tentative, since studies to date have not used mutagenesis strategies to map a PKC nitration site and unambiguously implicate a specific nitration event to a change in PKC function (activity, protein-protein interaction, targeting).
| VIII. OBSTACLES THAT STYMIE EFFORTS TO RESOLVE PKC ISOFORM-SPECIFIC FUNCTIONS |
|---|
|
TopPreviousNextReferences |
|---|
inhibitor is seriously undermined by evidence that rottlerin exerts inhibitory actions in PKC–/– cells and that rottlerin is not a particularly effective in vitro PKC inhibitor (39, 109, 189, 190). Even Ro 318220 and GF109203X, which are relatively specific inhibitors of PKC isoforms, exert off target actions to inhibit RSK and p70 S6 kinase in certain cellular contexts (2, 164, 165). Molecular overexpression strategies also must be interpreted with caution given the growing recognition that the subcellular compartmentalization and phosphorylation patterns of overexpressed PKCs (particularly kinase-inactive PKCs) may not faithfully recapitulate the properties of the native enzyme. Kinase-inactive PKCs aberrantly localized to detergent-insoluble cell fractions can promiscuously interact with nonphysiological binding partners (and may not be properly positioned to act as competitive inhibitors of the endogenous enzyme, Ref. 173). Furthermore, early studies from the Parker laboratory exposed effects of catalytically inactive (activation loop ThrAla) PKC, PKC, and PKC mutants to inhibit a common step in the processing/activation of all PKC isoforms, leading to a dominant-inhibitory effect on both the cognate enzymes and on PKC (63). These results emphasize that isoform-specific inhibition may be inherently trickier than generally acknowledged in the literature. While RNA interference gene silencing strategies may avoid some of the limitations inherent in overexpression studies, PKC knockout mouse models may be more problematic. Our recent studies suggest that the phenotype described for the PKC–/– mouse reflects the compensatory changes resulting from chronic deficiency of PKC from an early developmental stage (and not necessarily the physiological role of PKC in differentiated tissues, see sect. VIIIA3).
The other major strategy to interrogate PKC signaling function involves the overexpression of peptides designed to either promote or inhibit PKC translocation in cells. While these peptides certainly exert pronounced biological actions, the precise molecular mechanism(s) that underlie their actions may not necessarily be as straightforward as generally assumed for several reasons: 1) PKC is released from the membranes as a lipid-independent enzyme during oxidant stress. A peptide inhibitor that prevents RACK-driven PKC compartmentation to membranes would not prevent substrate phosphorylations in the soluble fraction of H2O2-treated cells. 2) Many PKCs localize to multiple subcellular compartments in a single cell (including surface membranes, lipid rafts, mitochondria, and nuclei). There is no a priori reason to assume that a single RACK anchors its cognate PKC isoform at all subcellular compartments (i.e., that a single peptide inhibitor should block PKC isoform translocation to distinct subcellular compartments). 3) There also is no a priori reason to assume that translocation modifier peptides selectively block PKC-RACK interactions, without blocking PKC interactions with non-RACK binding partners (for example, a PKC interaction with Src and PKC tyrosine phosphorylation). This entirely different interpretation for PKC inhibitor or activator peptide actions has never been adequately considered.
In addition to these well-established caveats that raise general concerns regarding standard investigative approaches routinely used to define PKC isoform specific functions, several caveats pertaining to studies of PKC isoforms that have not been sufficiently emphasized in the literature (and are underappreciated by the general research community) are discussed in the sections that follow.
A. PKC Isoform Cross-Talk in Cells
There is growing evidence that PKC isoforms do not always operate in isolation. PKC isoform cross-talk may be key for the functional integration of signaling networks in cells and may undermine the interpretation of knockout or overexpression studies.
1. PKC activity controls the spatiotemporal dynamics of PKC signaling in cells
There is a small (but consistent) literature that PKC activity itself influences PKC translocation and downregulation in cells (67). PKC activity is critical for the reversible cycling of cPKCs between the cytosol and plasma membrane in response to physiological stimuli such as G protein-coupled receptor agonists; PKC activity is less important for irreversible pharmacological responses to PMA (55). PKCs accumulate in cells treated with PKC inhibitors at least in part due to a defect in COOH-terminal autophosphorylation. However, chronic PKC inhibition also leads to a defect in PKC-dependent phosphorylation of the intermediate filament protein vimentin (which is required for vesicular transport and protein trafficking) and the accumulation of PKC in large β1-integrin-containing cytoplasmic vesicles, leading to abnormalities in integrin recycling to the plasma membrane and cell migration on a β1-integrin substrate (82, 83).
2. PKC activity regulates lipid metabolic enzymes that control DAG accumulation in cells
As noted in section VIC, certain PKC isoforms have been linked to the activation of PLD and the generation of PA and DAG (potentially amplifying PKC signaling responses). PKCs also regulate diacylglycerol kinases (DGKs), a family of nine mammalian enzymes that catalyze the phosphorylation of DAG to produce PA (a mechanism that terminates cPKC/nPKC signaling responses). DGKs have been subdivided into five groups based on regulatory domain motifs; individual DGK family members display distinct tissue expression patterns, catalytic properties, and modes of regulation, presumably allowing individual DGK enzymes to subserve distinct biological functions. Several DGK family members have been implicated as PKC binding partners or downstream targets. For example, PKC colocalizes with class I DGK at the plasma membrane in CHO-K1 cells; PKC-dependent DGK-S776/S779 phosphorylation results in increased DGK activity and feedback inhibition of PKC signaling responses (227). Class II DGKs ( and ) contain an NH2-terminal PH domain that contributes to membrane translocation and is the target of a cPKC-dependent regulatory phosphorylation that interferes with membrane translocation (81). The recent evidence that DGK gene inactivation leads to elevated DAG levels, increased PKC activity, and enhanced phosphorylation of PKC targets suggests that DGK inactivation may be a particularly important mechanism to amplify PKC signaling responses (36). Finally, class IV DGKs (, ) contain a NLS motif that shares homology with the phosphorylation domain of the MARCKs protein (a prominent PKC substrate) and is phosphorylated by conventional PKC isoforms. DGK is recovered in complexes with PKC and acts to negatively regulate PKC signaling in cells. However, a reciprocal effect of PKC to phosphorylate the DGK-MARCKs domain disrupts the PKC-DGK interaction, interferes with DGK nuclear localization, and reduces DGK activity. In this manner, PKC reverses the inhibitory effects of DGK and contributes to its own activation (126, 127). While there is still only limited information on the functional role of DGK-PKC interactions in physiologically relevant disease models, functionally important DGK-PKC cross-talk has been identified in the heart, where DGK overexpression prevents hypertrophic growth responses in both cardiomyocyte culture and transgenic mouse models (5, 210).
3. PKC-PKC cross-talk in cell culture models and genetically engineered mice
Studies in PKC–/– mice suggest that PKC exerts an inhibitory control on PKC (that is lost in the PKC–/– mouse). Klein et al. (98) reported that PKC protein expression and Thr505 phosphorylation are increased in PKC–/– (but not normal) hearts subjected to pressure overload. While Klein et al. did not identify changes in baseline PKC protein or phosphorylation in the absence of a hypertrophic stimulus, Gray et al. (70) identified increased PKC expression and PKC localization to perinuclear structures (a sign of chronic PKC activation) in resting cardiomyocytes isolated from PKC–/– mice.
Our recent studies using an adenoviral-mediated overexpression strategy also unambiguously place PKC downstream from a PKC signaling pathway in cardiomyocytes. However, the nature of this regulatory control runs counter to the expectation based on results obtained in genetically engineered mouse models; as noted in section IVB2, adenoviral-mediated PKC overexpression leads to a coordinate increase in PKC-Thr505/Tyr311/Tyr332 phosphorylation in cardiomyocyte cultures (170). This is a general mechanism that also is observed in other cell types, including cardiac fibroblasts and PKC–/– MEFs (202). These studies emphasize our still very rudimentary understanding of mechanisms that control nPKC isoform cross-talk. The results also emphasize that results obtained in PKC–/– mice (which describe the manner in which a particular mouse strain compensates for total body knockout of a signaling protein from embryonic life onward) should be interpreted with caution. Some aspects of a knockout phenotype may be pharmacological curiosities and not necessarily inform studies examining the physiological controls of nPKCs in highly differentiated tissues. These results also seriously undermine confidence in the literature that has exploited an adenoviral overexpression strategy to discriminate nPKC isoform functions in cells. In general, compensatory changes in protein abundance have been used as the sole criteria to exclude any PKC isoform cross-talk. Our results emphasize that this is not sufficient to exclude physiologically relevant forms of nPKC cross-talk, perhaps explaining some of the ambiguous results obtained in previous studies that have utilized this experimental strategy (156).
Our attempts to interrogate the molecular determinants of PKC-PKC cross-talk in cells also exposed a technical limitation imposed by conventional PKC overexpression strategies that is not widely recognized and deserves comment. A typical experiment, depicted in Figure 7B, shows that PKC overexpression leads to a time-dependent increase in native PKC-Thr505 and Tyr311 phosphorylation. However, the GFP-PKC fusion construct heterologously overexpressed in the same cells (that can be resolved from native PKC due to its slower migration in SDS-PAGE) is constitutively Thr505-phosphorylated and is not influenced by PKC overexpression (i.e., PKC-PKC cross-talk is not detected on the heterologously overexpressed enzyme). This feature of PKC overexpression studies is underappreciated and may limit its utility as a method to interrogate the physiological controls of PKC phosphorylation in highly differentiated tissues.
B. Some PKC-Directed Antibodies Are State Specific
Western blotting and immunoprecipitation experiments are predicated upon the assumption that anti-PKC antibodies recognize proteins of interest regardless of conformation or posttranslational modifications (i.e., that antibodies do not discriminate pools of enzyme with different phosphorylation patterns). However, we recently reported that a commercially available anti-PKC monoclonal antibody (from BD Transduction Laboratories, that has been used widely for almost a decade to detect and immunoprecipitate PKC) recognizes PKC in resting cardiomyocytes, but artifactually perceives a decline in PKC immunoreactivity under conditions of PMA activation (without any change in PKC protein expression, Ref. 174). We showed that PKC immunoreactivity is preserved when in vivo PMA treatment is performed in the presence of the PKC inhibitor GF109203X and that PKC immunoreactivity is restored by in vitro acid phosphatase treatment, suggesting the recognition epitope for the BD Transduction Laboratory anti-PKC antibody encompasses a site for PKC-dependent phosphorylation (or a site that is concealed as a result of a PKC-dependent phosphorylation elsewhere in the protein that alters conformation). Hence, the BD anti-PKC antibody is particularly ill-suited for studies that compare PKC expression levels in resting and PMA- (or growth factor-) activated samples or studies that examine the relationship between PKC phosphorylation and PKC downregulation (since it artifactually perceives PKC phosphorylation as a decline in total PKC protein). These findings suggest caution with regard to the interpretation of published literature using this antibody.
While conformationally sensitive anti-PKC antibodies represent obstacles that can confound research efforts, they also might offer a novel strategy that can be exploited to interrogate PKC functions. Based on the assumption that RACK binding sites are cryptic in the inactive conformation and exposed only following PKC activation, Souroujon et al. (193) used this approach to generate an antibody (termed 14E6, directed against residues 2–145 of PKC, encompassing the RACK binding site) that selectively recognizes antigenic determinants that are exposed following PKC activation by lipid cofactors; 14E6 does not recognize the inactive conformation of PKC (193). This antibody competes with RACK/β'-COP (425–905, which contains the PKC binding site) for PKC binding. By comparing 14E6 immunoreactivity to that of a commercial anti-PKC antibody (against the terminal 15 residues in the PKC-V5 domain), these investigators demonstrated that 1) PKC is localized in an inactive conformation that is not recognized by 14E6 in the nucleus of resting cardiomyocytes, 2) PKC localizes mainly to perinuclear and cross-striated structures upon activation (this activated form of PKC is recognized by 14E6), and 3) the activation-dependent increase in PKC staining with 14E6 is transient, presumably because the 14E6 epitope becomes masked when PKC binds RACK in cells.
C. Results of PKC Activity Assays Can Vary, Depending on Assay Conditions
The literature has generally viewed PKCs as generic kinases that phosphorylate substrates in a stereotypical manner (with PKC activity controlled exclusively by translocation events that control access to substrate, rather than any regulatory event that alters the enzyme). Many laboratories have used generic immunocomplex kinase assay kits (that are available from a number of commercial sources) to track PKC activity in cells. However, even a casual review of the literature reveals many inconsistencies (even for ostensibly identical experiments), suggesting that "the devil is in the details." Variables that can markedly alter the results of in vitro kinase assays and deserve greater attention in future studies include the following: 1) uncertainties with regard to the specificity and/or efficacy of antibodies used in immunoprecipitation experiments. Most commercially available antibodies have been characterized only superficially. While antibodies are generally assumed to recognize all of the enzyme in the cell (regardless of posttranslational modifications), recent experience in our laboratory and by others suggests otherwise. Many anti-PKC antibodies (particularly for PKC) do not quantitatively recover all of the immunoreactive enzyme from a cell lysate (at least in part because antibodies that interact with PKCs in a conformationally sensitive manner may be considerably more common than heretofore appreciated) (174). Antibody bias that can lead to the selective recovery of pools of enzyme with distinct posttranslational modifications and catalytic properties; this would seriously undermine the results of an experiment and is only rarely considered. The recent report that antibody binding to the PKC COOH terminus induces a conformational change that impacts on catalytic activity (i.e., antibody binding is sufficient to inhibit activity, Ref. 233) also could impact on the results of immune complex kinase assays and should be considered. 2) PKCs localize to detergent-insoluble subcellular compartments. The cytoskeleton is an important detergent-insoluble signaling compartment for several PKC isoforms. For example, PKC localizes as a tyrosine phosphorylated protein to the detergent-insoluble fraction of H2O2-treated cardiomyocytes. PKC isoforms that reside in detergent-insoluble compartments are not recovered in the extracts used for immunocomplex kinase assays; this pool of enzyme is not captured (and is not monitored) by traditional in vitro kinase assays. 3) Many PKCs coimmunoprecipitate with other serine-threonine kinases or regulatory proteins; the identity of the kinase activity in an immune complex kinase assay must be validated. The interaction between PKC and PKD (or Src kinases) constitutes just one example of a PKC-protein interaction that could impact on the results of immunocomplex kinase assays. Other serine/threonine kinases and phosphatases that also might coprecipitate and confound the interpretation of experiments must be considered. 4) The phosphorylation patterns of native and heterologously overexpressed PKCs frequently differ. Current concepts of the controls of PKC phosphorylation are based largely on studies of heterologously overexpressed enzymes. However, depicted in Figure 7B, native and heterologously overexpressed PKC phosphorylation patterns can differ dramatically even in the same cell. 5) Certain posttranslational modifications alter PKC enzymology (including cofactor requirements and substrate specificity). Most PKC kinase assays are predicated on the assumption that PKCs act as generic enzymes to phosphorylate target substrates in a stereotypical manner. Until quite recently, there was only limited anecdotal evidence that PKC activity is subject to more complex and elaborate controls (103). However, our recent studies identify a specific mechanism (involving Tyr311/Thr505 phosphorylation) that leads to a dramatic change in PKC-dependent phosphorylation of a physiologically relevant substrate, namely, cTnI (see sect. VC, Fig. 8). These studies emphasize that PKC kinase assays are influenced by the choice of the substrate. Since some stimuli alter PKC cofactor requirements, results may vary according to the composition of the assay buffer. Mechanisms that control the PKC enzymology in cells generally have not heretofore been considered; these newer concepts identify a real challenge for studies that track PKC activity in cells and emphasize the need for new technologies.
| IX. CHALLENGES AND OPPORTUNITIES FOR FUTURE RESEARCH: IDENTIFICATION OF CELLULAR TARGETS FOR INDIVIDUAL PKC ISOFORMS |
|---|
|
TopPreviousNextReferences |
|---|
A. Genetically Engineered Kinases
Through a mutagenesis approach directed at the gatekeeper residue, the ATP binding sites of various kinases have been engineered to accept structurally modified ATP analogs with bulky substitutions (that do not bind to endogenous enzymes in the cell; see sect. IV and Fig. 4) (184). This chemical genetic approach (which already has been applied to studies of PKA, Ref. 179) should provide a powerful and elegant strategy to resolve the cellular substrates of individual PKC isoforms.
B. FRET-Based Reporters That Track Intracellular PKC Activity
The Tsien laboratory (217) has developed a FRET-based reporter for PKC (CKAR) consisting of a PKC substrate (GGSGGRFRRFQTLKIKAKAGGSGG, which conforms to a PKC consensus phosphorylation motif and is a less favorable substrate for other kinases) tethered to a phosphothreonine-binding domain (the FHA2 domain from the yeast checkpoint protein rad53p) flanked by yellow- and cyan-shifted green fluorescent protein (YFP and CFP). PKC activation leads to the phosphorylation of the PKC substrate and an intramolecular interaction with the FHA2 phosphothreonine-binding domain, leading to a conformational change that increases FRET from CFP to YFP. Since the FHA2 binds the phosphorylated PKC substrate with relatively low affinity (10 µM), the intramolecular CKAR interaction is reversible, providing a continuous readout of PKC activity in cells (217). Forms of CKAR with targeting sequences that drive the reporter to specific subcellular localizations, including the plasma membrane, the Golgi, mitochondria, nucleus, and the cytosol have been generated and used to expose receptor-dependent PKC activation mechanisms that are dynamically regulated in time and space. Studies to date identify rapid/transient increases in calcium-sensitive PKC (presumably cPKC isoform activity) at the plasma membrane and in the cytosol that are followed by a slower and more sustained increase in PKC (tentatively identified as nPKCs) at the Golgi. These studies also identify a heretofore underestimated role for cellular phosphatases to control PKC activity, particularly in the nuclear compartment (59).
The Blumberg laboratory has taken a different approach to track PKC activity, generating a chimeric fusion consisting of PKC flanked by YFP and CFP at the NH2 and COOH termini. These studies build on the notion that conformational changes associated with PKC activation alter the distance between the PKC NH2 and COOH termini, leading to changes in FRET (as a measure of PKC activity) (20). This FRET-based PKC activity reporter (which shows native or near-native biological and biochemical activity, including in in vitro lipid cofactor binding assays and in translocation studies in cells) can be used to track PKC activity in cells and can be applied to high-throughput screens to evaluate prospective PKC ligands.
| X. CONCLUSIONS |
|---|
|
TopPreviousNextReferences |
|---|
) acting as "mini-processors" to integrate input from multiple cellular stimuli, using functionally important conformational changes in response to cofactors, translocation events, and posttranslational modifications (phosphorylation, tyrosine nitration, etc.) as a "language" to sense the intracellular microenvironment and adjust signaling output (Fig. 9C). This even more elaborate and nuance type of regulatory control is probably a general mechanism that pertains to many signaling proteins, suggesting that the field of signal transduction is still in a relatively early stage of the discovery process.
|
| GRANTS |
|---|
|
TopPreviousNextReferences |
|---|
| ACKNOWLEDGMENTS |
|---|
|
TopReferences |
|---|
| REFERENCES |
|---|
|
Top |
|---|
on the proliferative and tumorigenic properties of NIH 3T3 fibroblasts. Carcinogenesis 21: 887–891, 2000.: a novel intersection in cell adhesion and motility. EMBO J 22: 5390–5402, 2003.[CrossRef][Web of Science][Medline] prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice. Circulation 113: 60–66, 2006., facilitating PKC translocation via enhanced PKC-RACK2 interactions: a novel mechanism of NO-triggered activation of PKC. J Biol Chem 277: 15021–15027, 2002. by caspase-mediated processing and transduction of antiapoptotic signals. J Biol Chem 277: 41850–41856, 2002. is a phosphotyrosine binding domain. Cell 121: 271–280, 2005.[CrossRef][Web of Science][Medline]: implications for apoptosis. Mol Cell Biol 18: 6719–6728, 1998. is essential for its apoptotic effect in response to etoposide. Mol Cell Biol 22: 182–195, 2002.. Curr Biol 6: 1114–1123, 1996.[CrossRef][Web of Science][Medline] on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state. J Biol Chem 272: 3544–3549, 1997. to regulate a stress-activated protein kinase signaling complex. J Biol Chem 275: 35617–35623, 2000. modulate PKC activity and identify potential protein-protein interaction surfaces. J Biol Chem 282: 4113–4123, 2007. in the intact cell. J Biol Chem 280: 8164–8171, 2005. by phosphorylation. Biochem J 363: 537–545, 2002.[CrossRef][Web of Science][Medline] by peroxynitrite in stimulating cytosolic phospholipase A2 in pulmonary endothelium: involvement of a pertussis toxin sensitive protein. Biochemistry 44: 5246–5257, 2005.[CrossRef][Web of Science][Medline]: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet 72: 839–849, 2003.[CrossRef][Web of Science][Medline] activation loop phosphorylation in formyl-methionyl-leucyl-phenylalanine-induced phosphorylation of p47phox and rapid activation of nicotinamide adenine dinucleotide phosphate oxidase. J Immunol 179: 7720–7728, 2007.. J Biol Chem 278: 4972–4980, 2003. is an apoptotic lamin kinase. Oncogene 19: 2331–2337, 2000.[CrossRef][Web of Science][Medline] regulates protein kinase C and epidermal growth factor receptor signaling. Proc Natl Acad Sci USA 103: 15485–15490, 2006.. J Biol Chem 272: 29200–29206, 1997. in induction of apoptosis. J Biol Chem 272: 20317–20320, 1997.. J Biol Chem 272: 12747–12753, 1997. is required for apoptosis: identification of a novel nuclear import sequence. EMBO J 21: 6050–6060, 2002.[CrossRef][Web of Science][Medline] subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation. Circ Res 86: 293–301, 2000. by an ICE-like protease in apoptotic cells. EMBO J 14: 6148–6156, 1995.[Web of Science][Medline] to the plasma membrane requires both Ca2+ and PIP2 recognition by its C2 domain. Mol Biol Cell 17: 56–66, 2006. within structured membrane microdomains. J Biol Chem 282: 12450–12457, 2007.PKC but not PKC by caspase-3 during UV-induced apoptos. J Biol Chem 274: 10765–10770, 1999. compensates for the lack of involvement of its C2 domain in membrane recruitment. J Biol Chem 281: 1660–1669, 2006.. J Biol Chem 279: 3596–3604, 2004.. J Biol Chem 278: 41557–41565, 2003.. J Biol Chem 278: 2348–2355, 2003. translocates to the perinuclear region to activate phospholipase D1. J Biol Chem 279: 35702–35708, 2004. and - isoenzymes in renal mesangial cells. Biochemistry 37: 14556–14562, 1998.[CrossRef][Web of Science][Medline]1 is negatively regulated by conventional protein kinase C-dependent phosphorylation at Ser-22 and Ser-26 within the pleckstrin homology domain. Biochem J 382: 957–966, 2004.[CrossRef][Web of Science][Medline]-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 24: 3834–3845, 2005.[CrossRef][Web of Science][Medline] controls the traffic of β1-integrins in motile cells. EMBO J 21: 3608–3619, 2002.[CrossRef][Web of Science][Medline] to the plasma membrane in RBL-2H3 cells. Mol Biol Cell 14: 4885–4895, 2003. on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes. J Biol Chem 277: 12318–12323, 2002. in the Golgi complex. J Biol Chem 279: 12668–12676, 2004.-annexin V interaction: a required step in PKC translocation and function. J Biol Chem 281: 23218–23226, 2006./βII by ceramide: roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C-/β II on threonine 638/641. J Biol Chem 282: 20647–20656, 2007.. Circ Res 96: 748–755, 2005. in H2O2-treated cells and its activation by tyrosine kinase in vitro. Proc Natl Acad Sci USA 98: 6587–6592, 2001. on distinct tyrosine residues regulates specific cellular functions. J Biol Chem 275: 35491–35498, 2000. during nitric oxide-induced dopaminergic cell death. J Biol Chem 281: 2215–2224, 2006. is localized to the Golgi via its zinc-finger domain and modulates Golgi function. Proc Natl Acad Sci USA 92: 1406–1410, 1995. in hemopoietic cells. Lab Invest 81: 1087–1095, 2001.[Web of Science][Medline] is a negative regulator of antigen-induced mast cell degranulation. Mol Cell Biol 22: 3970–3980, 2002. phosphorylation site. J Biol Chem 271: 26404–26409, 1996. as an important autophosphorylation site for its enzymatic activity. J Biol Chem 272: 24550–24555, 1997. knockout mouse lenses are more susceptible to oxidative stress damage. J Exp Biol 209: 4371–4378, 2006. mutations in the C1B domain cause caspase-3-linked apoptosis in lens epithelial cells through gap junctions. Exp Eye Res 85: 113–122, 2007.[CrossRef][Web of Science][Medline] through the C1 domain. Effects on gap junctions. J Biol Chem 280: 13682–13693, 2005. regulation of gap junction activity through caveolin-1-containing lipid rafts. Invest Ophthalmol Vis Sci 44: 5259–5268, 2003. and the PKC C1b domains: identification of residues critical for PKC-mediated neurite induction. J Mol Biol 368: 951–965, 2007.[CrossRef][Web of Science][Medline] C1b domain crucial for protein kinase C--mediated induction of neurite outgrowth. J Biol Chem 280: 17910–17919, 2005. activity from activation loop phosphorylation: structural basis and altered functions in cells. J Biol Chem 281: 12102–12111, 2006. activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-B induction. Biochem J 361: 255–265, 2002.[CrossRef][Web of Science][Medline] function during T cell activation by Lck-mediated tyrosine phosphorylation. J Biol Chem 275: 3603–3609, 2000. C2-like domain is a binding site for actin and enables actin redistribution in neutrophils. Biochem J 357: 39–47, 2001.[CrossRef][Web of Science][Medline] in glioma cells. Biochem Biophys Res Commun 352: 431–436, 2007.[CrossRef][Web of Science][Medline] and the regulation of cell apoptosis. Cell Signal 19: 2165–2173, 2007.[CrossRef][Web of Science][Medline] with protein kinase C-: spatial regulation of diacylglycerol signaling. J Cell Biol 160: 929–937, 2003. phosphorylates and negatively regulates diacylglycerol kinase-. J Biol Chem 278: 39542–39547, 2003.. Differential roles of Ca2+ ligands and membrane binding residues. J Biol Chem 273: 17544–17552, 1998.. J Biol Chem 282: 21467–21476, 2007. reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352: 918–931, 2005.[CrossRef][Web of Science][Medline] to caveolae. J Cell Biol 141: 601–610, 1998. at the crossroad of NF-B and Jak1/Stat6 signaling pathways. Cell Death Differ 13: 702–711, 2006.[CrossRef][Web of Science][Medline] is a molecular switch in signal transduction of TNF-, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14: 1961–1969, 1995.[Web of Science][Medline] activation in cells. Science 283: 2085–2089, 1999. from 14-3-3: identification of PKC-binding sites. J Biol Chem 279: 52714–52725, 2004. A membrane binding model for Ca2+-independent C2 domains. J Mol Biol 311: 837–849, 2001.[CrossRef][Web of Science][Medline] in its protective effect against trail-induced apoptosis. J Biol Chem 280: 23643–23652, 2005. regulates the apoptosis and survival of glioma cells. Cancer Res 65: 7301–7309, 2005.. Structure 6: 885–894, 1998.[Medline] and nPKC. J Biol Chem 274: 34758–34764, 1999.. J Biol Chem 276: 13015–13024, 2001. and filamentous actin. J Biol Chem 273: 26790–26798, 1998. actively downregulates through caveolae-dependent traffic to an endosomal compartment. J Cell Sci 113: 2575–2584, 2000.[Abstract] and in the pituitary: a highly regulated mechanism involving a GD(E)E motif of the V3 region. J Cell Sci 117: 63–72, 2004.. Proteins 67: 709–719, 2007.[Medline] catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem 277: 33758–33765, 2002. and Src control PKC activation loop phosphorylation in cardiomyocytes. J Biol Chem 282: 23631–23638, 2007.-Y311 phosphorylation in cardiomyocyte caveolae. J Biol Chem. 283: 17777–17788, 2008. localization and activation mechanisms in cardiomyocytes. J Biol Chem 279: 19350–19361, 2004. in activation loop phosphorylations and PKC in hydrophobic motif phosphorylations. J Biol Chem 278: 14555–14564, 2003.: a cautionary note from the bench. Am J Physiol Cell Physiol 290: C750–C756, 2006. and - to the cytosol: implications in apoptosis. J Biol Chem 272: 2452–2458, 1997. translocation. J Biol Chem 279: 17617–17624, 2004. localises to the Golgi complex and induces apoptosis in neuroblastoma and Jurkat cells. Cell Death Differ 10: 662–675, 2003.[CrossRef][Web of Science][Medline] activity by C1–C2 domain interactions. J Biol Chem 277: 15277–15285, 2002.. Dependence on transphosphorylation of the activation loop. J Biol Chem 277: 45866–45873, 2002. tyrosine phosphorylation. J Biol Chem 276: 37986–37992, 2001.. Trends Pharmacol Sci 28: 453–458, 2007.[CrossRef][Medline] with Src family kinases in the RBL-2H3 mast cell line. Oncogene 16: 3357–3368, 1998.[CrossRef][Web of Science][Medline]-protein kinase C activation. J Biol Chem 279: 17617–17624, 2004.. J Biol Chem 275: 33289–33296, 2000.: mechanistic differences between protein kinases C and C. J Biol Chem 280: 19784–19793, 2005.. J Biol Chem 279: 29501–29512, 2004. and group IVa cytosolic phospholipase A2. J Biol Chem 278: 12452–12460, 2003.. J Biol Chem 280: 36452–36463, 2005.. Biochem J 384: 449–459, 2004.[CrossRef][Web of Science][Medline]: isoform substitution available at additional cost. Circ Res 96: 711–713, 2005. at threonine 505 is not a prerequisite for enzymatic activity. J Biol Chem 272: 6805–6811, 1997. for catalytic function. Role of glutamic acid 500 and autophosphorylation on serine 643. J Biol Chem 274: 8886–8892, 1999. in response to diacylglycerol. J Biol Chem 279: 40576–40583, 2004. phosphorylation of cardiac troponin I. Mol Cell. In press. and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J Biol Chem 275: 7470–7473, 2000. inhibits endothelin-1-induced cardiomyocyte hypertrophy. Circulation 111: 1510–1516, 2005. in T lymphocytes. EMBO J 24: 3869–3880, 2005.[CrossRef][Web of Science][Medline] targeting and accumulation at cell-cell contacts. Mol Cell Biol 21: 3351–3363, 2001. directly to phosphatidylserine. EMBO J 18: 6329–6338, 1999.[CrossRef][Web of Science][Medline] subspecies. Proc Natl Acad Sci USA 89: 10159–10163, 1992. phorbol-binding domain and study of protein-lipid micelle interactions. Biochemistry 36: 10709–10717, 1997.[CrossRef][Web of Science][Medline]. J Biol Chem 279: 50401–50409, 2004. via its interaction with protein kinase C-. J Biol Chem 281: 31627–31637, 2006.. J Biol Chem 281: 30768–30781, 2006. is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J 22: 1431–1441, 2003.[CrossRef][Web of Science][Medline]-mediated phosphorylation. J Biol Chem 282: 11549–11561, 2007., via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells. J Cell Biol 145: 713–726, 1999. in complex with phorbol ester. Cell 81: 917–924, 1995.[CrossRef][Web of Science][Medline] is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1. Cell Signal 18: 807–818, 2006.[CrossRef][Web of Science][Medline]This article has been cited by other articles:
|
|
 |
|
  C. Y. Chang and S. Mennerick Dynamic Modulation of Phasic and Asynchronous Glutamate Release in Hippocampal Synapses J Neurophysiol, January 1, 2010; 103(1): 392 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Pedersen, W. A. Macdonald, F. V. de Paoli, I. S. Gurung, and O. B. Nielsen Comparison of regulated passive membrane conductance in action potential-firing fast- and slow-twitch muscle J. Gen. Physiol., October 1, 2009; 134(4): 323 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Fenton, S. Komatsu, M. Ikebe, L. G. Shea, and J. G. Dobson Jr. Adenoprotection of the heart involves phospholipase C-induced activation and translocation of PKC-{varepsilon} to RACK2 in adult rat and mouse Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H718 - H725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu, X. Chen, S. M. MacDonnell, E. G. Kranias, J. N. Lorenz, M. Leitges, S. R. Houser, and J. D. Molkentin Protein Kinase C{alpha}, but Not PKC{beta} or PKC{gamma}, Regulates Contractility and Heart Failure Susceptibility: Implications for Ruboxistaurin as a Novel Therapeutic Approach Circ. Res., July 17, 2009; 105(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chang, D. Xiao, X. Huang, L. D. Longo, and L. Zhang Chronic hypoxia increases pressure-dependent myogenic tone of the uterine artery in pregnant sheep: role of ERK/PKC pathway Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1840 - H1849. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
